平成24年度 総括研究報告書

厚生労働科学研究費補助金

（厚生労働科学特別研究事業）

平成 25 年 3 月

愛知医科大学医学部教授

平成24年度 総括研究報告書

造血幹細胞移植の制度に関する国際比較分析に関する研究

研究代表者

小   寺   良   尚

厚生労働科学研究費補助金

（厚生労働科学特別研究事業）

平成 25 年 3 月

愛知医科大学医学部教授

平成24年度 総括研究報告書

造血幹細胞移植の制度に関する国際比較分析に関する研究

研究代表者

小   寺   良   尚

┠ ḟ

㹇㸬⥲ᣓ◊✲ሗ࿌

㐀⾑ᖿ⣽⬊⛣᳜ࡢไᗘ࡟㛵ࡍࡿᅜ㝿ẚ㍑ศᯒ࡟㛵ࡍࡿ◊✲

ᑠ ᑎ Ⰻ ᑦ

ϩ㸬◊✲ᡂᯝࡢห⾜࡟㛵ࡍࡿ୍ぴ⾲

Ϫ㸬◊✲ᡂᯝࡢห⾜≀㺃ูๅ

Gratwohl A, Baldomero H, Gratwohl M, Aljurf MD, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D.

Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.

Haematologica. 2013 Mar 18. [Epub ahead of print]

Halter JP, Walraven SM, Worel N, Bengtsson M, Hagglund H, Faveri G N, Shaw BE, SchmidtAH, Fechter M, Madrigal A, Szer J, Aljurf MD,Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y and Confer D.

Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data-A WBMT consensus document.

Bone Marrow Transplant. 2012, 1-6.

ู⣬㸱

ཌ⏕ປാ⛉Ꮫ◊✲㈝⿵ຓ㔠㸦ཌ⏕ປാ⛉Ꮫ≉ู◊✲஦ᴗ㸧

⥲ᣓ◊✲ሗ࿌᭩

㐀⾑ᖿ⣽⬊⛣᳜ࡢไᗘ࡟㛵ࡍࡿᅜ㝿ẚ㍑ศᯒ࡟㛵ࡍࡿ◊✲

◊✲௦⾲⪅ ᑠᑎⰋᑦ ឡ▱་⛉኱Ꮫ་Ꮫ㒊ᩍᤵ

◊✲せ᪨

ୡ⏺㐀⾑⣽⬊⛣᳜ࢿࢵࢺ࣮࣡ࢡ㸦WBMT㸧ࢆ௓ࡋ࡚ࠊᾏእ୺せᅜࡢ㐀⾑ᖿ⣽⬊⛣᳜࡟㛵ࢃࡿἲᚊ࣭つᐃ ࡢ᭷↓࡜ࡑࡢ㐠⏝ࡢᐇ᝟ࠊ㐀⾑ᖿ⣽⬊⛣᳜ࡢୡ⏺ࢧ࣮࣋࢖ࠊᝈ⪅࣭ࢻࢼ࣮ࡢᡂ⦼࣭Ᏻ඲ᢸಖࡢ௙⤌ࡳ࡟

ࡘࡁ◊✲ࡋࡓࠋἲᚊࢆ᭷ࡍࡿᅜࡣࡲࡔᑡ࡞ࡃࠊࡑࡢᚲせᛶࢆᥦၐࡍࡿᅜࡣከ࠿ࡗࡓࠋୡ⏺ࡢ㐀⾑ᖿ⣽⬊

⛣᳜ࡣ⣼✚୓౛ࢆ㉸࠼ࡿࡇ࡜ࡀ♧ࡉࢀࡿ࡜࡜ࡶ࡟ࠊᡃࡀᅜࢆྵࡴ࢔ࢪ࢔ࡢᡂ⦼ࡣḢ⡿࡜㐯Ⰽ࡞࠸ࡇ

࡜ࡀ᫂ࡽ࠿࡟࡞ࡗࡓࠋ⛣᳜⒪ἲ࡟ᚲせ࡞㐀⾑ᖿ⣽⬊ࢻࢼ࣮ᩘࡣୡ⏺࡛୓ே㸦௳ࠊ⮖ᖏ⾑ࢆྵࡴ㸧࡟

฿㐩ࡋ࡚࠸ࡓࠋࡇ࠺ࡋࡓᝈ⪅࣭ࢻࢼ࣮ࡢୡ⏺࡛ࣞ࣋ࣝࡢ⿵㊊ࢩࢫࢸ࣒ࡣࠊୡ⏺ಖ೺ᶵ㛵WHOࡢᥦၐ ࡍࡿ͆⛣᳜་⒪࡟࠾ࡅࡿ㆙ᡄ࡜┘ど͇ࡢල⌧໬࡛࠶ࡾࠊᐇ㊶ࣔࢹࣝ࡜⪃࠼ࡽࢀࡓࠋ

㸿㸬◊✲┠ⓗ

㐀⾑ᶵ⬟㞀ᐖ➼࡟ᑐࡍࡿ᭷ຠ࡞᰿἞ⓗ἞⒪࡛

࠶ࡿ㐀⾑ᖿ⣽⬊⛣᳜ࡣࠊᡃࡀᅜ࡟࠾࠸࡚ᖺ㛫⣙

௳๓ᚋࡀ⾜ࢃࢀ࡚࠾ࡾࠊ㔜せ࡞་⒪ᢏ⾡ࡢ 㸯ࡘ࡛࠶ࡿࠋ௒⯡ࠊ⛣᳜࡟⏝࠸ࡿ㐀⾑ᖿ⣽⬊ࡢ㐺 ษ࡞☜ಖ࡜ࠊ㐀⾑ᖿ⣽⬊⛣᳜ࡢ෇⁥࠿ࡘ㐺ṇ࡞ᐇ

᪋ࢆ┠ⓗ࡜ࡋ࡚ࠊ㐀⾑ᖿ⣽⬊⛣᳜࡟ಀࡿἲᚊ㸦㆟

ဨ❧ἲ㸧ࡀࠊ௒ᅜ఍࡬ࡢᥦฟࢆぢ㎸ࡲࢀ࡚࠸ࡿࠋ ᡃࡀᅜࡢ㐀⾑ᖿ⣽⬊⛣᳜ࡣࠊᾏእ࡜ࡢẚ㍑࡟

࠾࠸࡚ࡶࡑࡢᡂ⦼ࡣඃࢀ࡚࠾ࡾࠊᡃࡀᅜࡢ㐀⾑

ᖿ⣽⬊⛣᳜ࡢᬑཬ⋡ࡣୡ⏺ⓗ࡟ࡶࢺࢵࣉࢡࣛࢫ

࡟࠶ࡿ࡜ゝࢃࢀ࡚࠸ࡿ୍᪉ࠊἲⓗ࡞ᇶ┙ࡀ༑ศ

࡛࡞࠸୰ࠊ⌧ሙࡢດຊࡸᕤኵ࡟ࡼࡗ࡚ࠊࡇࢀ

ࢆⓎᒎࡉࡏ࡚ࡁࡓࠋ

⌧ᅾࠊ㐀⾑ᖿ⣽⬊ࡢᥦ౪ࡣࠊᅜෆ࡟ᑐࡍࡿࡶ

ࡢ࡟࡜࡝ࡲࡽࡎࠊ୰ᅜࠊ⡿ᅜࠊḢᕞྛᅜ➼ࡢᾏ እ࡟ᑐࡋ࡚┦஫ࡢ㐃ᦠࡀࡼࡾάⓎ໬ࡋ࡚࠾ࡾࠊ ᡃࡀᅜ࡟ᑐࡍࡿᅜ㝿ⓗ࡞ᮇᚅࡣ኱ࡁ࠸ࠋ᭦࡟⌧

ᅾ▱ࡽࢀ࡚࠸ࡿ㐀⾑ᶵ⬟㞀ᐖࡸࠊᝏᛶ⭘⒆࡟ᑐ ࡍࡿ἞⒪࡜ࡋ࡚ࡢᙺ๭ࡢࡳ࡞ࡽࡎࠊᅜෆእ࡟࠾

࠸࡚ࠊ⬻ᛶ㯞⑷ࡸϨᆺ⢾ᒀ⑓࡞࡝ࠊ⌧ᅾ᰿἞ࡍ

ࡿࡇ࡜ࡀᅔ㞴࡞⑌⑓࡟ᑐࡍࡿ἞⒪࡜ࡋ࡚ࡢ◊✲

ࡀ㐍ࡵࡽࢀࡿ࡞࡝ࠊ௒ᚋⓎᒎࡢవᆅࡀ኱ࡁ࡞ศ 㔝࡛࠶ࡿࠋ

ࡇࡢࡼ࠺࡞≧ἣ࡟࠾࠸࡚ࠊ㐀⾑ᖿ⣽⬊⛣᳜ࡢ ㅖእᅜࡢไᗘࡢ≉ᚩࡸࠊㅖእᅜᨻᗓࡢᨻ⟇ⓗ࣭

⤒῭ⓗ㛵୚ࡢ⌧≧ࢆ▱ࡿࡇ࡜࡟ࡼࡾࠊᡃࡀᅜࡢ 㐀⾑ᖿ⣽⬊⛣᳜ไᗘ࣭ᨻ⟇࡟㛵ࡍࡿᇶ‽➼࡟཯

ᫎࡍࡿࡇ࡜ࡀᮇᚅ࡛ࡁࡿࠋ

ࡲࡓ⌧ᅾࠊ㐀⾑ᖿ⣽⬊ࡢ࠶ࡗࡏࢇࡸ౪⤥ࡣࠊ 㦵㧊⛣᳜᥎㐍㈈ᅋࡸ⮖ᖏ⾑ࣂࣥࢡ࡟ࡼࡗ࡚⾜ࢃ

ࢀ࡚࠸ࡿࡀࠊ࠶ࡗࡏࢇ࡟᫬㛫ࡀ࠿࠿ࡿࡇ࡜ࠊ㐺 ษ࡞ࢻࢼ࣮ࡀぢࡘ࠿ࡽ࡞࠸ሙྜࡀ࠶ࡿࡇ࡜ࠊࡲ

ࡓ⮖ᖏ⾑ࣂࣥࢡࡢᩚഛࡢᚲせᛶ➼ࡢㄢ㢟ࡀᣦ᦬

ࡉࢀ࡚࠸ࡿୖ࡟ࠊ௒ᚋࡣ㧗㱋໬➼࡟క࠸ࠊ㐀

⾑ᖿ⣽⬊⛣᳜ࡢ㔜せᛶࡣࡲࡍࡲࡍ㧗ࡲࡿࡶࡢ࡜

ண᝿ࡉࢀ࡚࠸ࡿࠋ

ᮏ◊✲ࡣࠊᡃࡀᅜ࡛ึࡵ࡚ࠊㅖእᅜ࡟࠾ࡅࡿ㐀

⾑ᖿ⣽⬊⛣᳜ࡢ఩⨨࡙ࡅࡸࠊᅜࡢ㛵୚ࠊ㈝⏝ࡢ ศ㓄᪉ἲࠊ࠶ࡗࡏࢇࡢ᪉ἲࡸ⛣᳜ᡂ⦼➼ࢆẚ㍑

᳨ウࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊᡃࡀᅜ࡟࠾ࡅࡿ㐀⾑ᖿ

⣽⬊⛣᳜ࡢࡉࡽ࡞ࡿⓎᒎ࡜ࠊᅜ㝿༠ຊࢆ᥎㐍ࡍ

ࡿ࡟࠶ࡓࡗ࡚ࡢㅖㄢ㢟࡟ࡘ࠸᳨࡚ウࡋࡼ࠺࡜ࡍ

ࡿࡶࡢ࡛࠶ࡿࠋ

㹀㸬◊✲᪉ἲ

ᮏ◊✲䛿䚸㻌 㐀⾑ᖿ⣽⬊⛣᳜䛻㛵㐃䛧䚸㻌 ඛ㐍ᅜ ୪䜃䛻᪂⯆ᅜ䜢ᑐ㇟䛸㻌 䛧䛶ᅜෆཬ䜃ㅖእᅜ䛾㐀

⾑ᖿ⣽⬊⛣᳜䛻䛚䛡䜛ᩥ⊩䚸㻌 ཬ䜃ᚲせ䛻ᛂ䛨䛶ㅖ እᅜ䛾㛵㐃Ꮫ఍㻌 䞉㻌 㛵㐃ᅋయ➼䛻ᑐ䛧䛶ㄪᰝ䜢⾜

䛔䚸㻌 ྍ⬟䛺㝈䜚ヲ⣽䛻⌧≧䜢ᢕᥱ䛩䜛䛯䜑䛻௨ୗ

䛾◊✲䜢⾜䛖䚹㻌

䠍䠅APBMT/WBMT/WHO䜢௓䛧䛯䚸㐀⾑⣽⬊⛣᳜

䛻㛵䜟䜛᝟ሗ཰㞟㻌

ᡃ䛜ᅜྠᵝ䚸㐀⾑⣽⬊⛣᳜ඛ㐍ᅜ㻌 䠄⡿ᅜ䚸ⱥᅜ䚸 䝗䜲䝒䚸䝣䝷䞁䝇䠅䜢୰ᚰ䛸䛧䛶䚸୰ᅜ䚸㡑ᅜ䛺䛹䜰䝆 䜰䜢ྵ䜑䛯ㅖእᅜ䛻䛚䛡䜛䚸㻌 㐀⾑⣽⬊⛣᳜⒪ἲ䛾 ᬑཬ⋡䚸㻌 㦵㧊䞉ᮎᲈ⾑䝞䞁䜽䚸㻌 ⮖ᖏ⾑䝞䞁䜽䛾ᅾ 䜚᪉䛸බ㈝䛻䜘䜛ຓᡂ䛾ᐇែ䚸ᝈ⪅䚸䝗䝘䞊Ⓩ㘓䞉䝣 䜷䝻䞊䜰䝑䝥䛾௙⤌䜏䛸බ㈝䛻䜘䜛ຓᡂ䛾ᐇែ䚸㐀

⾑ᖿ⣽⬊䛾್ẁ䚸㐀⾑ᖿ⣽⬊᥇ྲྀ䞉⛣᳜᪋タ䛾ㄆ ᐃᇶ‽䚸㻌 㐀⾑ᖿ⣽⬊⛣᳜⒪ἲ䛸௚䛾⣽⬊⒪ἲ䜔

෌⏕་⒪䛸䛾㛵ಀ䛻䛴䛝᝟ሗ཰㞟䜢⾜䛔䚸㻌 ௒⯡᪂ 䛯䛻❧ἲ໬䛜ணᐃ䛥䜜䛶䛔䜛㐀⾑ᖿ⣽⬊⛣᳜ἲ 䠄௬⛠䠅㻌 䛻ᇶ䛵䛟ㅖ᪋⟇䛻཯ᫎ䛥䛫䜛䚹㻌

䛺䛚䚸⡿ᅜ䚸䝇䜲䝇➼䛻䛚䛔䛶䛿㐀⾑⣽⬊⛣᳜㛵 㐃ἲ᱌䛜୍㒊᪋⾜䛥䜜䛶䛔䜛䛜䚸≉䛻᪥ᮏ䛸㐀⾑

ᖿ⣽⬊⛣᳜䛾┦஫༠ຊ䛜㐍䜣䛷䛔䜛⡿ᅜ䚸䝗䜲䝒䛻 䛴䛔䛶䛿䚸㻌 ⌧ᆅㄪᰝ䜢⾜䛖䚹㻌

䜎䛯䚸WHO䛷䛿㛵㐃ἲ᱌䛾ᇶᮏⓗ⪃䛘䜔ἲ᱌䛜 ᑐ㇟䛸䛩䜉䛝㡿ᇦ➼䛻䛴䛝䚸㻌 ㏆ᖺ୍ᐃ䛾ぢゎ䜢ฟ 䛧䛴䛴䛒䜛䚹㻌 䛣䜜䜙䛻ᑐ䛩䜛WHO䛾ពྥ➼䛻䛴䛔

䛶䜒䚸㻌APBMT / WBMT / WHO 䜢௓䛧䛶㈨ᩱ཰㞟

䛩䜛䛸䛸䜒䛻䚸ྛᅜ䞉ᆅᇦ䛻䛚䛡䜛ไᗘ䛸䛾┦஫ẚ㍑

䜢⾜䛖䚹㻌

䠎䠅㻌 ᝈ⪅䞉䝗䝘䞊䛾Ᏻ඲ᛶ䜔⮫ᗋᡂ⦼䛻㛵䛩䜛䝕䞊 䝍䛾䚸㻌 ୡ⏺つᶍ䛷䛾㞟ィ䛸ゎᯒ㻌

APBMT / WBMT䛜ಖ᭷䛧䛶䛔䜛ᝈ⪅䝕䞊䝍䚸㻌 䜎 䛯䝗䝘䞊䝕䞊䝍䛻䛴䛔䛶䚸㻌 ẚ㍑᳨ウ䛷䛝䜛ᙧᘧ䜈 䛾ኚ᥮䜢ጤク䛧䚸䝕䞊䝍䜢཰㞟䛩䜛䚹䛣䜜䜢⏝䛔䛶䚸

ྛᅜ䛻䛚䛡䜛㐀⾑ᖿ⣽⬊⛣᳜䛾ᑐ㇟⑌ᝈ䜔ேᩘ䚸

⮫ᗋᡂ⦼䛺䛹䛾⌧≧䜢ẚ㍑䛩䜛䚹㻌

᭦䛻䚸㻌 ୡ⏺䛾㠀⾑⦕䝪䝷䞁䝔䜱䜰䝗䝘䞊䛾Ᏻ඲ᛶᢸ ಖ≧ἣ䜢᳨ド䛩䜛䚹㻌 䛭䜜䛸୪⾜䛧䚸㻌 ᡃ䛜ᅜ䛾ᮎᲈ

⾑ᖿ⣽⬊䝗䝘䞊䜢౛እ䛸䛧䛶䚸㻌 䛣䛖䛧䛯௙⤌䜏䛾ᯟ እ䛻䛒䛳䛯䚸㻌 ୡ⏺⾑⦕䝗䝘䞊䛾Ᏻ඲ᛶᢸಖ≧ἣ䛻 䛴䛔䛶䜒ㄪᰝ䜢⾜䛖䚹㻌

䛣䜜䜢䜒䛳䛶䚸㻌 ྛᅜไᗘ䛻䛚䛡䜛㐀⾑ᖿ⣽⬊⛣

᳜䛾ᐇែ䜢᳨ド䛧䚸㻌 ᭦䛺䜛⛣᳜ᡂ⦼䛾ྥୖ䛻䛴䛺 䛜䜛䛣䛸䜢♧䛩䛸䛸䜒䛻䚸ᡃ䛜ᅜ䛷⾜䜟䜜䛶䛔䜛䜘䛖 䛺䚸㻌 ⾑⦕⪅䜒ྵ䜑䛯䚸඲䛶䛾㐀⾑⣽⬊䝗䝘䞊஦๓

Ⓩ㘓㻌 䞉㐺᱁ᛶ䝏䜵䝑䜽䝅䝇䝔䝮䛜䚸㻌 䝗䝘䞊䛾Ᏻ඲䜢 ᢸಖ䛩䜛ୖ䛷᭷⏝䛷䛒䜛䛣䛸䜢ド᫂䛩䜛䚹㻌

㸦೔⌮㠃䜈䛾㓄៖䠅㻌

ᝈ⪅䚸䝗䝘䞊䛾᝟ሗ䛿㛵୚䛩䜛඲䛶䛾⤌⧊䞉ᶵᵓ䛻 䛚䛔䛶༏ྡ໬䛥䜜䛶䛚䜚䚸ୟ䛴䛭䜜䜙䛾䝕䞊䝍䝉䞁 䝍䞊䜈䛾Ⓩ㘓䞉฼⏝䛻㛵䛧䛶䛿㛵୚䛩䜛඲䛶䛾⤌

⧊䞉䛻䛚䛔䛶೔⌮ᑂᰝጤဨ఍ཪ䛿䛭䜜䛻┦ᙜ䛩䜛 ጤဨ఍䛻䛚䛔䛶ᢎㄆ䜢ཷ䛡䛶䛔䜛䚹㻌

㻌

㹁㸬◊✲⤖ᯝ 㸯㸧

㸯㸧APAPBMTBMT, WBMT WBMT ࡢᴫせ࡜ᴫせ࡜WHWHO࡜ࡢ㛵ಀ࡜ࡢ㛵ಀ㸸 WBMTࡣ⾲-1࡟♧ࡍ㐀⾑⣽⬊⛣᳜㛵㐃18ᅜ㝿

⤌⧊༶ࡕࠊAPBMT (Asia-Pacific Blood and Marrow Transplantation Group)ࠊABMTRR (The Australasian Bone Marrow Transplant Recipient Registry)ࠊEBMT (European Group for Blood and Marrow Transplantation)ࠊ CIBMTR (Center for International Blood and Marrow Transplant Research), WMDA (World Marrow Donor Association), AABB (American Association of Blood Banks),

EMBMT (The East Mediterranean Blood and Marrow Transplantation Group), Netcord, Eurocord, ESH (The European School for Haematology), EFI (The European Federation for Immunogenetics), ISCT (The International Society for Cellular Therapy), JACIE (Joint Accreditation Committee-ISCT), BMDW (Bone Marrow Donors Worldwide), FACT (Foundation for the Accreditation of Cellular Therapy), ASBMT (American Society for Blood and Marrow Transplantation), ASHI

(American Society for Histocompatibility and Immunogenetics), EMBIDS (European Marrow Donor Information System)ࠊࢆ᮰ࡡࡿ

2

㐃㑥࡛࠶ࡾࠊ2006ᖺ࡟タ❧ࡉࢀࡓࠋAPBMT㸦⌧

ᅾ࢔ࢪ࢔19࢝ᅜ/ᆅᇦ㸹᪥ᮏࠊ㡑ᅜࠊྎ‴ࠊ୰ᅜࠊ

࣍ࣥࢥࣥࠊࣔࣥࢦࣝࠊ࢖ࣥࢻࢿࢩ࢔ࠊ࣐࣮ࣞࢩ࢔ࠊ

ࣇ࢕ࣜࣆࣥࠊࢩ࣏࣮ࣥ࢞ࣝࠊ࣋ࢺࢼ࣒ࠊࢱ࢖ࠊࣂ

ࣥࢢࣛࢹࢩࣗࠊ࣑࣐࣮ࣖࣥࠊ࢖ࣥࢻࠊࣃ࢟ࢫࢱࣥࠊ

࢖ࣛࣥࠊ࣮࢜ࢫࢺࣛࣜ࢔ࠊࢽ࣮ࣗࢪ࣮ࣛࣥࢻࠊࡀ ཧຍ㸧ࡶࡑࡢ୍ဨ࡛࠶ࡿࠋWBMTࡣ2013ᖺ1

᭶ࠊWHOࡢබㄆNGO࡜࡞ࡗࡓࠋ 㸰㸧

㸰㸧APBMT/WBMT/WHO ࢆ௓ࡋࢆ௓ࡋࡓࠊ㐀⾑⣽ࠊ㐀⾑⣽⬊

⛣᳜࡟㛵

⛣᳜࡟㛵ࢃࡿ᝟ሗ཰ࡿ᝟ሗ཰㞟:

㐀⾑⣽⬊

㐀⾑⣽⬊⛣᳜ࡢୡ⏺᳜ࡢୡ⏺࡟࠾ࡅࡿᬑ࠾ࡅࡿᬑཬ⋡㸸

WHOᇶ‽ࡢୡ⏺༊ศࠊ࢔ࢪ࢔࣭ኴᖹὒᆅᇦࠊ༡

໭࢔࣓ࣜ࢝ᆅᇦࠊ࣮ࣚࣟࢵࣃᆅᇦࠊ࢔ࣇ࣭ࣜ࢝ᮾ ᆅ୰ᾏᆅᇦẖ࡟ࠊᅜู㐀⾑⣽⬊⛣᳜ᖺ㛫ᐇ᪋ᩘࢆ

WBMT ࡜ࡋ࡚ㄪᰝࡋࡓࠋேཱྀ 1000 ୓ேᙜࡓࡾ

300 ௳௨ୖࡢ㐀⾑ᖿ⣽⬊⛣᳜ࢆᐇ᪋ࡋ࡚࠸ࡿᅜ ࡣ࢔ࢪ࢔࡛ࡣᡃࡀᅜ࡜࣮࢜ࢫࢺࣛࣜ࢔/ࢽ࣮ࣗࢪ

࣮ࣛࣥࢻࠊ༡໭࢔࣓࡛ࣜ࢝ࡣ⡿ᅜࠊ࣮ࣚࣟࢵࣃ࡛

ࡣࢻ࢖ࢶࠊ࢖ࢠࣜࢫࠊࣇࣛࣥࢫࠊ࢖ࢱࣜ࢔ࠊ໭Ḣ

➼ࡢḢᕞෆ࡛ࡢඛ㐍ᅜㅖᅜࠊ࢔ࣇ࡛ࣜ࢝ࡣᮍࡔᏑ ᅾࡋ࡚࠸࡞࠿ࡗࡓࠋḟ࡟ୖグ༊ศᆅᇦูࡢ㐀⾑⣽

⬊⛣᳜⣼✚ᐇ᪋ᩘ୪ࡧ࡟ࠊࡑࢀࡽࢆ඲࡚ྜࢃࡏࡓ ୡ⏺࡛ࡢ⣼✚ᐇ᪋ᩘࢆㄪᰝࡋࡓࠋୡ⏺ࡢ⥲⣼✚ᩘ

ࡣ2013ᖺึ㢌࡟100୓౛ࢆ㉸࠼ࠊᆅᇦู࡛ࡣḢ

ᕞ53%ࠊ༡໭࢔࣓ࣜ࢝31%ࠊ࢔ࢪ࢔15%ࠊ࢔ࣇ

࣭ࣜ࢝ᮾᆅ୰ᾏ㸯㸣ࡢ㡰࡛࠶ࡗࡓࠋᚑࡗ࡚࢔ࢪ࢔

ᆅ༊࡛⾜ࢃࢀࡓ⣼✚ᩘࡣ⣙15୓౛࡛࠶ࡾࠊෆᡃ ࡀᅜࡀ⣙7୓౛ࢆᐇ᪋ࡋ࡚࠸ࡿࠋ

㸱㸧㦵㧊࣭

㸱㸧㦵㧊࣭ᮎᲈ⾑ࣂࣥᮎᲈ⾑ࣂࣥࢡࠊࢡࠊ ⮖ᖏ⾑⮖ᖏ⾑ࣂࣥࢡࡢᅾࣂࣥࢡࡢᅾࡾ

᪉࡜බ㈝

᪉࡜බ㈝࡟ࡼࡿຓᡂࡼࡿຓᡂࡢᐇែᐇែ

㐀⾑ᖿ⣽⬊ࣂࣥࢡࡢ≧ἣࡣࠊWBMTࡢ࣓ࣥࣂ࣮

⤌⧊ࡢ୍ࡘ࡛࠶ࡿ BMDW ࢆ௓ࡋ࡚▱ࡿࡇ࡜ࡀ ฟ᮶ࡿࠋ⌧ᅾHLA᝟ሗࢆ᭷ࡍࡿ㦵㧊࣭ᮎᲈ⾑ࢻ ࢼ࣮ཬࡧಖᏑ⮖ᖏ⾑ࡢ⥲ᩘࡣ53࢝ᅜࠊ116ࣞࢪ

ࢫࢺ࣮ࣜ㸦ࣂࣥࢡ㸧࠿ࡽࡢྜィ࡛21,650,000ே/

௳ࢆ㉸࠼࡚࠸ࡿࠋ116ࣂࣥࢡࡢෆ46ࣂࣥࢡࡣ⮖

ᖏ⾑༢⊂ࣂࣥࢡࠊ᫂ࡽ࠿࡟࡞ࡗ࡚࠸ࡿ࡜ࡇࢁ࡛1

ࣂࣥࢡ㸦⡿ᅜ㦵㧊ࣂࣥࢡ㸸NMDP㸧ࡢࡳࡀ㦵㧊࣭

ᮎᲈ⾑࣭⮖ᖏ⾑ࢆᢅࡗ࡚࠸ࡿࡀࠊࡇࢀࡣ⡿ᅜෆ࡛

௚ࡢ⮖ᖏ⾑ࣂࣥࢡࡀᏑᅾࡋ࡞࠸ࡇ࡜ࢆព࿡ࡋ࡚

࠸ࡿࢃࡅ࡛ࡣ࡞࠸㸦ᚋ㏙㸧ࠋṧࡾ 70 ࡣ㦵㧊࣭ᮎ ᲈ⾑ࣂࣥࢡ࡛ࡑࢀࡀ 53 ࢝ᅜ࡟Ώࡗ࡚࠸ࡿ࠿ࡽࠊ 㦵㧊࣭ᮎᲈ⾑ࣂࣥࢡ࡟࠿ࡂࡗ࡚ࡳ࡚ࡶ1ᅜෆ࡟2 ࡘ௨ୖࡢࡶࡢࢆ᭷ࡍࡿᅜࡀ࠶ࡿࡇ࡜࡟࡞ࡿࠋ௨ୗ

ᅜࡈ࡜࡟㦵㧊࣭ᮎᲈ⾑ࣂࣥࢡᩘ㸸⮖ᖏ⾑ࣂࣥࢡᩘ

ࢆ♧ࡍ㸹࢔ࣝࢮࣥࢳࣥ 1㸸1ࠊ࢔࣓ࣝࢽ࢔ 1㸸0ࠊ

࣮࢜ࢫࢺࣛࣜ࢔㸯㸸㸯ࠊ࣮࢜ࢫࢺࣜ࢔ 1㸸1ࠊ࣋

ࣝࢠ࣮1㸸1ࠊࣈࣛࢪࣝ1㸸0ࠊࣈࣝ࢞ࣜ࢔ 1㸸0ࠊ

࢝ࢼࢲ1㸸1ࠊ୰ᅜ2㸸0ࠊࢡࣟ࢔ࢳ࢔1㸸1ࠊ࢟ࣉ

ࣟࢫ2㸸1ࠊࢳ࢙ࢥ2㸸1ࠊࢹ࣐࣮ࣥࢡ2㸸1ࠊࣇ࢕

ࣥࣛࣥࢻ1㸸1ࠊࣇࣛࣥࢫ1㸸1ࠊࢻ࢖ࢶ1㸸2ࠊࢠ

ࣜࢩࣕ 2㸸2ࠊ࣍ࣥࢥࣥ1㸸0ࠊࣁ࣮ࣥ࢞ࣜ1㸸0ࠊ

࢖ࣥࢻ2㸸0ࠊ࢖ࣛࣥ1㸸2ࠊ࢔࢖ࣝࣛࣥࢻ1㸸0ࠊ

࢖ࢫ࢚ࣛࣝ3㸸2ࠊ࢖ࢱࣜ࢔1㸸1ࠊ᪥ᮏ1㸸1㸦ᮾ

ி⮖ᖏ⾑ࣂࣥࢡࡀ၏୍ BMDW ࡬ຍ┕Ⓩ㘓ࡋ࡚

࠸ࡿ㸧ࠊ㡑ᅜ0㸸2㸦㡑ᅜࡢࢯ࢘ࣝ኱Ꮫࢆ୰ᚰ࡜ࡋ

ࡓ㦵㧊࣭ᮎᲈ⾑ࣂࣥࢡ࡜KMDPࡣ᭱㏆⤫ྜ࡟㏆

࠸≧ែ࡟࠶ࡿ࡜⪺ࡃࡀࠊ࡞ࡐ࠿BMDW࡟ࡣⓏ㘓 ࡋ࡚࠸࡞࠸㸧ࠊࣜࢺ࢔ࢽ࢔1㸸0ࠊ࣐ࢣࢻࢽ࢔1㸸

0ࠊ࣓࢟ࢩࢥ 1㸸1ࠊ࢜ࣛࣥࢲ 1㸸1ࠊࢽ࣮ࣗࢪ࣮

ࣛࣥࢻ1㸸0ࠊࢼ࢖ࢪ࢙ࣜ࢔1㸸0ࠊࣀ࢙ࣝ࢘࢖1㸸

0ࠊ࣏࣮ࣛࣥࢻ 3㸸1ࠊ࣏ࣝࢺ࢞ࣝ 1㸸0ࠊ࣮࣐ࣝ

ࢽ࢔1㸸0ࠊࣟࢩ࢔3㸸1ࠊࢭࣝࣅ࢔1㸸0ࠊࢩࣥ࢞

࣏࣮ࣝ1㸸0ࠊࢫࣟࣂ࢟࢔1㸸1ࠊࢫࣟ࣋ࢽ࢔1㸸1ࠊ ༡࢔ࣇࣜ࢝1㸸0ࠊࢫ࣌࢖ࣥ2㸸1ࠊࢫ࢙࣮࢘ࢹࣥ

1㸸1ࠊࢫ࢖ࢫ 1㸸1ࠊྎ‴ 1㸸5ࠊࢱ࢖ 1㸸1ࠊࢺ

ࣝࢥ2㸸1ࠊⱥᅜ3㸸2㸦Anthony Nolan⮖ᖏ⾑㒊 㛛ࢆྵࡴ㸧ࠊ࢔ࣛࣈ㐃ྜ1㸸0ࠊ࢘ࣝࢢ࢔࢖1㸸0ࠊ 㸯㸧APBMT, WBMT ࡢᴫせ࡜WHO࡜ࡢ㛵ಀ

ྜ⾗ᅜ 3㸸7㸦NMDP ⮖ᖏ⾑㒊㛛ࢆྵࡴ㸧ࠋබ㈝

ࡢ ຓ ᡂ ࡟ 㛵 ࡋ ࡚ ࡛ ࠶ ࡿ ࡀ ࠊ ⡿ ᅜ 㦵 㧊 ࣂ ࣥ ࢡ 㸦NMDP㸧ࡣἲ࡟ᇶ࡙ࡃᨻᗓຓᡂࢆཷࡅࠊⱥᅜ 㦵 㧊 ࣂ ࣥ ࢡ 㸦Anthony Nolan Bone Marrow Donor Trust㸧ࡶᨻᗓ⿵ຓ㔠ࢆᚓ࡚࠸ࡿࠋࣇࣛࣥ

ࢫࡢ㦵㧊ࣂࣥࢡࡣᨻᗓෆ⤌⧊࡛࠶ࡿࠋࢻ࢖ࢶ㦵㧊

ࣂࣥࢡࡣ⡿ᅜNMDP࡟ḟࡂୡ⏺➨஧఩ࡢつᶍ࡛

࠶ࡿࡀẸ㛫ᅋయ࡛࠶ࡿࠋ 㸲㸧

㸲㸧㐀⾑ᖿ㐀⾑ᖿ⣽⬊⛣᳜⣽⬊⛣᳜ἲ㸦㐀⾑ᖿ⣽㸦㐀⾑ᖿ⣽⬊ࡢ್ẁࠊ⬊ࡢ್ẁࠊ㐀⾑㐀⾑

ᖿ⣽⬊᥇ྲྀ

ᖿ⣽⬊᥇ྲྀ࣭⛣᳜᪋タ࣭⛣᳜᪋タࡢㄆᐃᇶ‽ࡢㄆᐃᇶ‽ࠊ 㐀⾑ᖿ⣽㐀⾑ᖿ⣽⬊

⛣᳜⒪ἲ࡜௚᳜⒪ἲ࡜௚ࡢ⣽⬊⒪ἲࡢ⣽⬊⒪ἲࡸ෌⏕་⒪ࡸ෌⏕་⒪࡜ࡢ㛵ಀࢆ࡜ࡢ㛵ಀࢆ

ྵࡴ㸧࡟

ྵࡴ㸧࡟㛵ࡍࡿୡ⏺ࡍࡿୡ⏺࢔ࣥࢣ࣮ࢺࣥࢣ࣮ࢺࡢᐇ᪋ᐇ᪋

ㅖእᅜ࡟࠾ࡅࡿ㐀⾑ᖿ⣽⬊⛣᳜ࡢ఩⨨࡙ࡅࢆ࠶

ࡁࡽ࠿࡟ࡍࡿ┠ⓗ࡛ࠊ㸯㸧㛵㐃ࡍࡿἲᚊࡸ㏻㐩ࡢ

᭷↓ࠊ㸰㸧㹆㹊㸿᝟ሗࡢ⟶⌮ࡢ௙᪉㸦༢୍ࠊබⓗࠊ

࢔ࢡࢭࢫ㸧ࠊ㸱㸧◊✲┠ⓗ࡛ࡢ㐀⾑⣽⬊ࡢ㌿⏝ࡢ

ྍྰࠊ㸲㸧㈝⏝ࡢ㓄ศ᪉ἲࠊ㸳㸧౯᱁ࡀタᐃࡉࢀ

࡚࠸ࡿ࠿㸦᥇ྲྀᩱࠊ⛣᳜ᩱ㸧ࠊ㸴㸧ᝈ⪅㈇ᢸࡢ๭

ྜࠊ㸵㸧᩷᪕ࡢ᪉ἲ 㸦༢୍࢔ࢡࢭࢫࠊ⛣᳜ࢳ࣮

࣒ࡢ௙஦ࠊᦙ㏦㸦≉࡟⮖ᖏ⾑㸧ࠊ㸶㸧ᝈ⪅㈇ᢸ㔠 ࡢ᭷↓ࠊ㸷㸧⑕౛㐺᱁ᇶ‽㸦ไ㝈ࡢ᭷↓㸧ࠊ㸯㸮㸧 ࢻࢼ࣮㐺᱁ᇶ‽ࠊ➼࡟㛵ࡍࡿᅜ㝿࢔ࣥࢣ࣮ࢺࢆࠊ WBMTࢆ௓ࡋ࡚⾜ࡗࡓࠋィ㸯㸶࢝ᅜ࠿ࡽᅇ⟅ࢆ

ᚓࡓࡀࠊࡑࢀࡽࡣ㹕㹀㹋㹒ᵓᡂ୺せᅜ㝿⤌⧊࡛࠶

ࡿCIBMTRࡢ⡿ᅜ㸪EBMTࡢ࣮࢜ࢫࢺࣜ࢔ࠊࢫ

࢙࣮࢘ࢹࣥࠊ࣏࣮ࣛࣥࢻ㸪APBMTࡢ୰ᅜࠊ㤶 ࠊ 㡑ᅜࠊ࢖ࣥࢻࠊࣃ࢟ࢫࢱࣥࠊࣇ࢕ࣜࣆࣥ㸪࣮࢜ࢫ ࢺࣛࣜ࢔/ࢽ࣮ࣗࢪ࣮ࣛࣥࢻࠊEMBMTࡢࢧ࢘ࢪ

࢔ࣛࣅ࢔ࢆྵࡳࠊᅇ⟅⪅ࡣࡑࢀࡒࢀࡢᆅᇦࢆ௦⾲

ࡍࡿேࡓࡕ࡛ࠊࡑࡢᆅᇦࡢ⌧≧ࢆࠊᅜࢆࡲࡓ࠸࡛

ᅇ⟅ࡋࡓࡶࡢ࡜࡞ࡗ࡚࠸ࡿࠋ௨ୗ࡟࢔ࣥࢣ࣮ࢺᅇ

⟅⤖ᯝࡢせⅬࢆグࡍ㸹 ᅇ⟅⤖ᯝࡢせᯝࡢせⅬ

㸯㸧㐀⾑ᖿ⣽⬊⛣᳜࡟㛵ࡍࡿἲᚊ/㏻㐩ࡢ᭷↓㸸

≉໬ࡉࢀࡓἲᚊ࠶ࡾ㸹16.7㸣ࠊ௚ࡢ㛵㐃ࡍࡿἲᚊ

࡟⤌ࡳධࢀࡽࢀ࡚Ꮡᅾ㸹50㸣ࠊ࡞ࡋ㸹33.3㸣ࠊ㸰㸧 ἲᚊࡢᚲせᛶ㸸ᚲせ࠶ࡾ㸹66.7㸣ࠊᚲせ↓ࡋ㸹 33.3㸣ࠊ㸱㸧ἲᚊ᪋⾜ᚋ㈗ᅜ/ᆅᇦࡢ㐀⾑ᖿ⣽⬊

⛣᳜㡿ᇦࡣⓎᒎࡋࡓ࠿㸸Ⓨᒎࡋࡓ㸹50㸣ࠊᚲࡎ ࡋࡶࡑ࠺࡛ࡣ࡞࠸㸹50㸣ࠊ㸲㸧ἲᚊࡣ⛣᳜/᥇ྲྀ

᪋タࣞ࣋ࣝ࡟࠾࠸࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚ࡋࡓ࠿㸸ࡣ

࠸㸹58.3㸣ࠊ࠸࠸࠼㸹33.3㸣ࠊศ࠿ࡽ࡞࠸㸹8.3㸣ࠊ 㸳㸧ἲᚊࡣ㦵㧊࣭ᮎᲈ⾑ᖿ⣽⬊ࣂࣥࢡࣞ࣋ࣝ࡟࠾

࠸࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚ࡋࡓ࠿㸸ࡣ࠸㸹75㸣ࠊ࠸

࠸࠼㸹16.7㸣ࠊศ࠿ࡽ࡞࠸㸹8.3㸣ࠊ㸴㸧ἲᚊࡣ

⮖ᖏ⾑ࣂࣥࢡࣞ࣋ࣝ࡟࠾࠸࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚

ࡋࡓ࠿㸸ࡣ࠸㸹33.3㸣ࠊ࠸࠸࠼㸹25㸣ࠊศ࠿ࡽ࡞

࠸㸹41.7㸣ࠊ㸵㸧ἲᚊࡣࢻࢼ࣮HLA ࢹ࣮ࢱࢭࣥ

ࢱ࣮ࣞ࣋ࣝ࡟࠾࠸࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚ࡋࡓ࠿㸸ࡣ

࠸㸹66.7㸣ࠊ࠸࠸࠼㸹25㸣ࠊศ࠿ࡽ࡞࠸㸹8.3㸣ࠊ 㸶㸧ἲᚊࡣ⛣᳜⑕౛ࢹ࣮ࢱࢭࣥࢱ࣮ࣞ࣋ࣝ࡟࠾࠸

࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚ࡋࡓ࠿㸸ࡣ࠸㸹58.3㸣ࠊ࠸࠸

࠼㸹33.3㸣ࠊศ࠿ࡽ࡞࠸㸹8.3㸣ࠊ㸷㸧ἲᚊࡣ᪂ ࡋ࠸◊✲ࡢࣞ࣋ࣝ࡟࠾࠸࡚⛣᳜ࡢⓎᒎ࡟ᐤ୚ࡋ ࡓ࠿㸸ࡣ࠸㸹16.7㸣ࠊ࠸࠸࠼㸹50㸣ࠊศ࠿ࡽ࡞࠸㸹 33.3㸣ࠊ㸯㸮㸧ἲᚊࡣ་⒪㈝ࡢ࡛ࣞ࣋ࣝ⛣᳜ࡢⓎ

ᒎ࡟ᐤ୚ࡋࡓ࠿㸸ࡣ࠸33.3㸣ࠊ࠸࠸࠼㸹58.3㸣ࠊ ศ࠿ࡽ࡞࠸㸹8.3㸣ࠊ㸯㸯㸧㈗ᅜ/ᆅᇦ࡟ࡣྠ✀㐀

⾑ᖿ⣽⬊⛣᳜ࡢ㐺᱁ᇶ‽ࡣ࠶ࡿ࠿㸸ࡣ࠸㸹82.4㸣ࠊ

࠸࠸࠼㸹17.7㸣ࠊ㸯㸰㸧㐺᱁ᇶ‽ࢆ‶ࡓࡍᝈ⪅ᩘ

ࢆ᥎ᐃࡍࡿୖ࡛࡝ࡢࡼ࠺࡞ࢹ࣮ࢱࢆ⏝࠸ࡿ࠿㸸ᅜ ࡢࢹ࣮ࢱ㸹33.3㸣ࠊᏛ఍ࡢࢹ࣮ࢱ㸹46.7㸣ࠊࣂࣥ

ࢡࢹ࣮ࢱ㸹13.3㸣ࠊࡑࡢ௚㸹6.7㸣ࠊ㸯㸱㸧㈗ᅜ/

ᆅᇦࡣ㐀⾑⣽⬊⛣᳜㡿ᇦࡢᏛ఍ࢆ᭷ࡍࡿ࠿㸸≉໬

ࡉࢀࡓᏛ఍ࢆ᭷ࡍࡿ㸹37.5㸣ࠊ௚Ꮫ఍ࡢ୍㒊࡜ࡋ

࡚᭷ࡍࡿ㸹25㸣ࠊ௒ࡢ࡜ࡇࢁᣢࡗ࡚࠸࡞࠸㸹37.5㸣ࠊ 㸯㸲㸧ㄡࡀ⛣᳜་⒪㈝ࢆ㈇ᢸࡍࡿ࠿㸸බⓗ೺ᗣಖ 㝤㸹93.8㸣ࠊ⚾ⓗ೺ᗣಖ㝤㸹12.5㸣ࠊ௚ࡢᨭ᥼ᇶ

4

㔠㸦◊✲㈝➼㸧㸹12.5㸣ࠊᝈ⪅ࡀ㈇ᢸࡍࡿ㸹18.8㸣ࠊ ࡑࡢ௚㸹12.5㸣ࠊ㸯㸳㸧୺἞་ࡀ⛣᳜࡟⏝࠸ࡿࡇ

࡜ࡀฟ᮶ࡿ㐀⾑ᖿ⣽⬊ࢆ᳨⣴ࡋ᭱⤊ⓗ࡟ධᡭ࡟

⮳ࡿࡲ࡛ࡢ㐣⛬࡛ࠊ࢔ࢡࢭࢫ࣏࢖ࣥࢺࡣᗄࡘ࠿㸸

୍ࡘ㸹68.8㸣ࠊ」ᩘ㸹31.3㸣ࠊ㸯㸴㸧㦵㧊࣭ᮎᲈ

⾑ᖿ⣽⬊ࣂࣥࢡࡸ⮖ᖏ⾑ࣂࣥࢡ࡛ಖᏑࡉࢀ࡚࠸

ࡿ⣽⬊ࡣ◊✲⏝࡟⏝࠸ࡿࡇ࡜ࡶチྍࡉࢀ࡚࠸ࡿ

࠿㸸ࡣ࠸㸹31.3㸣ࠊ࠸࠸࠼㸹37.5㸣ࠊࡑࡢ௚㸹31.3㸣ࠊ 㸯㸵㸧㦵㧊ᖿ⣽⬊ࡢ౯᱁ࡣタᐃࡉࢀ࡚࠸ࡿ࠿㸸ࡣ

࠸㸹37.5㸣ࠊ࠸࠸࠼㸹62.5㸣ࠊ㸯㸶㸧ᮎᲈ⾑ᖿ⣽

⬊ࡢ౯᱁ࡣタᐃࡉࢀ࡚࠸ࡿ࠿㸸ࡣ࠸㸹37.5㸣ࠊ࠸

࠸࠼㸹62.5㸣ࠊ㸯㸷㸧⮖ᖏ⾑ࡢ౯᱁ࡣタᐃࡉࢀ࡚

࠸ࡿ࠿㸸ࡣ࠸㸹18.8㸣ࠊ࠸࠸࠼㸹81.3㸣ࠊ㸰㸮㸧 ᅜ㝿ⓗ࡟ࢥࣥࢭࣥࢧࢫࢆᚓ࡚࠸ࡿ⛣᳜㐺ᛂᇶ‽

௨እࡢᇶ‽ࡀ࠶ࡿ࠿㸸ࡣ࠸㸦୍㒊ไ㝈ࡉࢀ࡚࠸

ࡿ㸧㸹25㸣ࠊ࠸࠸࠼㸹75㸣ࠊ㸰㸯㸧ୖグࢆไ㝈ࡋ

࡚࠸ࡿࡶࡢࡣ㸸ἲᚊ/つᐃ㸹50㸣ࠊಖ㝤㸹0㸣ࠊࡑ ࡢ௚㸹50㸣ࠊ㸰㸰㸧ไ㝈ࡢせᅉࡀᖺ㱋ࡢሙྜ㸸 50ṓࡲ࡛㸹25㸣ࠊ65ṓࡲ࡛㸹25㸣ࠊ70ṓࡲ࡛㸹 25㸣ࠊ↓ᅇ⟅㸹25㸣ࠊไ㝈ࡢせᅉࡀ⑌ᝈ≧ែࡢ ሙྜ㸸࠸ࡃࡘ࠿ࡢ⑌ᝈ࡟࠾࠸࡚ࡣ≉ู⏦ㄳࡀᚲせࠊ

἞⒪᢬ᢠᛶࡣไ㝈࠶ࡾࠊࡑࡢ௚㸹⛣᳜᪋タࡢタഛࠊ 㸰㸱㸧ࡑࡢ௚ࡶࡋ᝟ሗࡀ࠶ࢀࡤ㸸ࠋ

㸳㸧ୖグ

㸳㸧ୖグ࢔ࣥࢣ࣮ࢺࣥࢣ࣮ࢺ࡟࠾࠸࡚ἲ࠾࠸࡚ἲᚊ࣭つᐃ࠶࣭つᐃ࠶ࡾ࡜ࡋ ࡓᅜࡢ୺

ࡓᅜࡢ୺࡞ἲᚊ࣭つἲᚊ࣭つᐃ

a)⡿ᅜ㸸Public Law 109-129-Dec.20, 2005,

“Stem Cell Therapeutic and Research Act of 2005”

b) Public Law 111-264-Oct. 8, 2010, “Stem Cell Therapeutic and Research Reauthorization Act of 2010”

c) Private Cord Blood Banking: Experiences and Views of Pediatric Hematopoietic Cell Transplantation Physicians. 2009

d) 㹃㹀㹋㹒㸸On the issue of cord blood (CB) transplantation and private banking the EBMT.

e) 㡑ᅜ㸸Enactment of a low for governmental support of the use of cord blood, and ethical issues.

f)㡑ᅜ㸸The prospect of the government management for cord blood in Korea-At the time of enactment of the [Cord blood management and research act]-

ࡇࢀࡽࡢෆࠊ㈨ᩱ-㸱㸪㸲࡟♧ࡍࡶࡢࡣࠊCW Bill Young Program࡜࿧ࡤࢀࠊᡃࡀᅜࡢ͆㐀⾑ᖿ⣽

⬊⛣᳜᥎㐍ἲ㸦␎⛠㸧͇࡟ᑐᛂࡍࡿࡶࡢ࡜⪃࠼ࡽ

ࢀࡿࠋ 㸴㸧⡿ᅜ

㸴㸧⡿ᅜࡢἲᚊ࡟㛵ἲᚊ࡟㛵ࡍࡿ㆑⪅ᣍࡿ㆑⪅ᣍ࡬࠸஦ᴗ࠸஦ᴗ

ୖ㏙ࡢ⡿ᅜࡢἲᚊ(W Bill Young Program)࡟ᑐ ࡍࡿ⌮ゎࢆ῝ࡵࠊࡑࢀࡢᇳ⾜ᚋࡢ≧ἣࢆᢕᥱࡍࡿ

┠ⓗ࡛ࠊCIBMTR ࠿ࡽJ Douglas Rizzo༤ኈࢆ

ᣍ⪸ࡋබ㛤ウㄽ఍➼ࢆ⾜ࡗࡓࠋᮏᣍ⪸ࡣ඲㡯ࡢ⡿

ᅜࡢἲᚊ࡛࠶ࡿCW Bill Young Programࡢᴫせ

࡜ᇳ⾜≧ἣࢆᢕᥱࡍࡿୖ࡛᭷┈࡛࠶ࡗࡓࠋࡇࡇ࡟

බ㛤ウㄽ఍㸦ຮᙉ఍㸧ࡢࣞࢪ࣓ࢆ཰㘓ࡋ࡚࠾ࡃࠋ

ࠕ㐀⾑ᖿ⣽⬊⛣᳜ࡢไᗘ࡟㛵ࡍࡿᅜ㝿ẚ㍑ศᯒࠖ

◊✲

Prof. Douglas Rizzoࢆᅖࢇ࡛ࡢຮᙉ఍ ࣞࢪ࣓

Summary of Presentation of CW Bill Young Cell Transplantation Program

ࣅࣝࣖࣥࢢ⛣᳜ࣉࣟࢢ࣒ࣛࡢᇳ⾜≧ἣ January 15, 2013

The U. S. Stem Cell Therapeutic and Research Act of 2005 (Public Law 109-129) established the C.W. Bill Young Cell Transplantation 㸲㸧㐀⾑ᖿ⣽⬊⛣᳜ἲ㸦㐀⾑ᖿ⣽⬊ࡢ್ẁࠊ㐀⾑

ᖿ⣽⬊᥇ྲྀ࣭⛣᳜᪋タࡢㄆᐃᇶ‽ࠊ 㐀⾑ᖿ⣽⬊

⛣᳜⒪ἲ࡜௚ࡢ⣽⬊⒪ἲࡸ෌⏕་⒪࡜ࡢ㛵ಀࢆ

ྵࡴ㸧࡟㛵ࡍࡿୡ⏺࢔ࣥࢣ࣮ࢺࡢᐇ᪋

ᅇ⟅⤖ᯝࡢせⅬ

Program (the Program) to collect, analyze, and report on outcomes for all allogeneic

transplants and on other therapeutic uses of blood stem cells. The Program was

re-authorized in 2010 (Public Law #111-264).

2005ᖺ࡟⡿ᅜᖿ⣽⬊἞⒪࣭◊✲ἲ㸦බἲ109-129㸧

࡟ᇶ࡙ࡁࠊࣅࣝࣖࣥࢢ⛣᳜ࣉࣟࢢ࣒ࣛ㸦௨ୗࣉࣟ

ࢢ࣒ࣛ㸧ࡀ඲࡚ࡢྠ✀⛣᳜୪ࡧ࡟ࡑࡢ௚ࡢᖿ⣽⬊

ࢆ⏝࠸ࡿ἞⒪࡟㛵ࢃࡿ᝟ሗࡢ཰㞟ࠊゎᯒࠊᡂ⦼ࡢ ሗ࿌ࢆ┠ⓗ࡜ࡋ࡚ᐃࡵࡽࢀࡓࠋࣉࣟࢢ࣒ࣛࡣ 2010ᖺ࡟᭦᪂ࡉࢀ࡚࠸ࡿࠋ

CIBMTR was awarded a contract with the Health Resources and Services Administration (HRSA) to administer the Stem Cell

Therapeutic Outcomes Database (SCTOD) for the Program; National Marrow Donor

Program (NMDP) was also awarded contracts to administer other portions of the Program.

CIBMTR㸦ᅜ㝿㹀㹋㹒◊✲ࢭࣥࢱ࣮㸧ࡀࣉࣟࢢ

࣒ࣛ୰ࡢSCTOD㸦ᖿ⣽⬊἞⒪ᡂ⦼ࢹ࣮ࢱ࣮࣋ࢫࠊ

௨ୗࢹ࣮ࢱ࣮࣋ࢫ㸧ࢆᇳ⾜ࡍࡿ⤌⧊࡜ࡋ࡚㑅ࡤࢀ

ཌປ┬࡜ዎ⣙ࡋࡓࠋNMDP㸦⡿ᅜ㦵㧊ࣂࣥࢡ㸧 ࡣࣉࣟࢢ࣒ࣛࡢ௚ࡢ㒊ศࢆᇳ⾜ࡍࡿ⤌⧊࡜ࡋ࡚

㑅ࡤࢀྠ┬࡜ዎ⣙ࡋࡓࠋ

The Program goals are to make information about HCT available to patients, families, health care professionals and the public; to help create better processes for identifying unrelated matched marrow donors, peripheral blood stem cell donors, and cord blood units through one electronic system; to increase the numbers of unrelated adult volunteer donors and cord blood units available; and to expand research to improve patient outcomes.

CIBMTR has grown to meet the needs of the SCTOD contract, which in turn enhances CIBMTR’s ability to facilitate research conducted under U24-CA76518.

ࣉࣟࢢ࣒ࣛࡢ┠ᶆࡣ㸯㸧ᝈ⪅ࠊᐙ᪘ࠊ་⒪㛵ಀ⪅ࠊ

୍⯡ᅜẸࡢࡓࡵࡢᖿ⣽⬊⛣᳜᝟ሗࢆసᡂࡍࡿࡇ

࡜ࠊ㸰㸧㠀⾑⦕㦵㧊ࠊᮎᲈ⾑ࢻࢼ࣮ࠊಖᏑ⮖ᖏ⾑

࡬ࠊ༢୍ࡢ㟁Ꮚ፹యࢩࢫࢸ࣒ࢆ㏻ࡌ᳨࡚⣴࡛ࡁࡿ

ࡼࡾⰋ࠸ࢩࢫࢸ࣒ࢆసࡿࡇ࡜ࠊ㸱㸧㠀⾑⦕ࢻࢼ࣮

࡜⮖ᖏ⾑ࣘࢽࢵࢺࢆቑࡸࡍࡇ࡜ࠊ㸲㸧⛣᳜ᡂ⦼ྥ

ୖ ࡢ ࡓ ࡵ ࡢ ◊ ✲ ࢆ ᣑ ᙇ ࡍ ࡿ ࡇ ࡜ ࠊ ࡛ ࠶ ࡿ ࠋ

CIBMTR ࡣዎ⣙࡟ᇶ࡙ࡃࢹ࣮ࢱ࣮࣋ࢫࡢせ௳ࢆ

‶ࡓࡍ࡭ࡃᣑ኱ࡉࢀࠊ⤖ᯝⓗ࡟UA24㸫CA76518

࡛つᐃࡉࢀࡓ◊✲ࢆᨭ࠼ࡿCIBMTRࡢᶵ⬟ࡀᙉ

໬ࡉࢀࡓࠋ

Dr. Rizzo, Project Director for the SCTOD will provide an overview of the Program,

describing each of the components, their responsibilities and relationships in the Program. These components include the Advisory Council to the Secretary of Health and Human Services, the SCTOD, the Cord Blood Coordinating Center, a Bone Marrow Coordinating Center, an Office of Patient Advocacy/Single Point of Access, and a

National Cord Blood Inventory. The benefits of the Program will be described from the

perspective of the HCT recipient, volunteer unrelated donors, transplant centers,

researchers, the government, and third-party payers (insurers and employers). Limitations of the Program will also be addressed.

Dr.Rizzo ࡣࢹ࣮ࢱ࣮࣋ࢫࡢࣉࣟࢪ࢙ࢡࢺ㈐௵⪅

࡛࠶ࡿࡀࠊࣉࣟࢢ࣒ࣛࡢᴫせ࡜ࡑࡢෆᐜࠊࣉࣟࢢ

6

࣒ࣛ࡜ࢹ࣮ࢱ࣮࣋ࢫࣉࣟࢪ࢙ࢡࢺ࡜ࡢ㛵ಀ୪ࡧ

࡟ࣉࣟࢪ࢙ࢡࢺഃࡢ㈐ົ࡟ࡘ࠸࡚ሗ࿌ࡍࡿ࡛࠶

ࢁ࠺ࠋෆᐜࡢ୰࡟ࡣ㸯㸧ཌ⏕⛉Ꮫᑂ㆟఍ࠊ㸰㸧ࣉ

ࣟࢪ࢙ࢡࢺࡢᐇែࠊ㸱㸧⮖ᖏ⾑ࢥ࣮ࢹ࢕ࢿ࣮ࢺࢭ

ࣥࢱ࣮ࠊ㸲㸧㦵㧊㸦ᮎᲈ⾑㸧ࢥ࣮ࢹ࢕ࢿ࣮ࢺࢭࣥ

ࢱ࣮ࠊ㸳㸧ᝈ⪅┦ㄯ/༢୍࢔ࢡࢭࢫࡢࡓࡵࡢ࢜ࣇ

࢕ࢫࠊ㸴㸧ᅜࡢ⮖ᖏ⾑ಖᏑ௳ᩘࠊࡀྵࡲࢀࡿࠋࣉ

ࣟࢢ࣒ࣛࡢ฼Ⅼࢆ㸯㸧⛣᳜ᝈ⪅ࠊ㸰㸧࣎ࣛࣥࢸ࢕

࢔ࢻࢼ࣮ࠊ㸱㸧⛣᳜ࢭࣥࢱ࣮ࠊ㸲㸧◊✲⪅ࠊ㸳㸧

⾜ᨻࠊ㸴㸧⤒㈝࡟㛵ࢃࡿ➨୕⪅㸦ಖ㝤఍♫ࡸ㞠⏝

୺㸧ࡢほⅬ࠿ࡽ㏙࡭ࡿ࡛࠶ࢁ࠺ࠋ୍᪉ࣉࣟࢢ࣒ࣛ

ࡢ㝈⏺࡟ࡘ࠸࡚ࡶゝཬࡍࡿࠋ

The impact of the Program on transplantation in the United States, especially increasing use of cord blood as a source of stem cells for transplantation will be briefly discussed. One particular benefit of the Program, research through the SCTOD, will be highlighted. The Outcomes database serves as a platform for public reporting, and robust tool to advance the field of HCT through research. CIBMTR has successfully leveraged the requirements of the SCTOD, funding from the National

Institutes of Health, and the benefits of the collaborative academic environment to facilitate meaningful research to improve survival, access to HCT and understand late outcomes of HCT. The importance of the academic environment and the expertise it affords to stimulate collaborative research will be emphasized.

⡿ᅜෆࡢ⛣᳜࡟ᑐࡍࡿࣉࣟࢢ࣒ࣛࡢຠᯝࠊ≉࡟⮖

ᖏ⾑⛣᳜ࡢቑຍ࡟ࡘ࠸࡚ࡶ㏙࡭ࡿࠋ᭦࡟ࣉࣟࢢࣛ

࣒ࡢ≉➹ࡍ࡭ࡁ฼Ⅼ࡜ࡋ࡚ࡢࠊࢹ࣮ࢱ࣮࣋ࢫࢆ௓

ࡋࡓ◊✲࡟ࡘ࠸࡚㏙࡭ࡿࠋࢹ࣮ࢱ࣮࣋ࢫࡣᗈሗࡢ ᇶ┙࡛࠶ࡾࠊ◊✲άືࢆ௓ࡋ࡚ᖿ⣽⬊⛣᳜ศ㔝ࢆ

㐍ᒎࡉࡏࡿᙉຊ࡞ᡭẁ࡛ࡶ࠶ࡿࠋCIBMTR ࡣࢹ

࣮ࢱ࣮࣋ࢫ࡜ࡋ࡚せồࡉࢀ࡚࠸ࡿࡶࡢࢆ඘㊊ࡍ

ࡿࡇ࡜࡟ᡂຌࡋࠊNIH ࠿ࡽࡢ㈨㔠ࢆཷࡅࠊཪᖿ

⣽⬊⛣᳜ࡢ⏕Ꮡ⋡ྥୖࠊᖿ⣽⬊⛣᳜࡟⮳ࡿࡲ࡛ࡢ 㐨➽ࠊᖿ⣽⬊⛣᳜ᝈ⪅ࡢ㛗ᮇணᚋ࡬ࡢ⌮ゎ➼ࡢࡓ

ࡵࡢ᭷ຠ࡞◊✲ࢆᐇ᪋ࡍࡿୖ࡛ᚲせ࡞◊✲ᶵ㛵 㸦኱Ꮫ㸧࡜ࡢⰋࡁ㛵ಀࢆ☜❧ࡋ࡚࠸ࡿࠋ࢔࢝ࢹ࣑

ࢵࢡ࡞⎔ቃ࡜ඹྠ◊✲ࢆ᥎㐍ࡍࡿୖ࡛ࡢᑓ㛛ᐙ ࡢᚲせᛶ࡟ࡘ࠸࡚ࡶᙉㄪࡋࡓ࠸ࠋ

㸵㸧

㸵㸧CICIBMTR/NMDPBMTR/NMDPࡢどᐹࡢどᐹ

๓㡯࠿ࡽᚓࡽࢀࡓ᝟ሗࢆᇶ࡟ࠊ⡿ᅜἲᚊᇳ⾜ࡢ୰

᰾ⓗᙺ๭ࢆᯝࡓࡍCIBMTR, NMDPࡢどᐹࢆᐇ

᪋ࡋࡓࠋどᐹ㡯┠ࡣ௨ୗࡢዴࡃ࡛࠶ࡿ㸹

CIBMTR ࡟࠾࠸࡚ࡣࠊ࢔㸧SCTOD ࡢࡓࡵࡢࢫ

࣮࣌ࢫࠊసᴗ⪅ࡢᑓ㛛࡜ேᩘࠊ࢖㸧ᑗ᮶௒ᅇࡢᡃ ࡀᅜࡢἲᚊ࡟ᇶ࡙࠸࡚సࡽࢀࡓ♫ᅋἲே᪥ᮏ㐀

⾑⣽⬊⛣᳜ࢹ࣮ࢱࢭࣥࢱ࣮ࡀ┤࡟ࢥࣥࢱࢡࢺࡀ

ྲྀࢀࡿせே࡜ࡢ㠃఍ࠊ࢘㸧SCTOD㸦CIBMTR㸧

࡜㹌㹋㹂㹎ཬࡧ௚ࡢࢹ࣮ࢱࢆᚲせ࡜ࡍࡿ⤌⧊㛫 ࡢࢹ࣮ࢱ஺᥮ࡢ᪉ἲ㸦ఱ࠿ࣞࢠ࣮ࣗࣞࢩࣙࣥࡀᅾ

ࡿ࠿➼ࡶྵࡵ㸧ࠋ

NMDP࡟࠾࠸࡚ࡣࠊ࢔㸧The Office of Patient Advocacy/Single Point of Access (OPA/SPA)࡟

ࡘ࠸࡚ࠊNMDP࡜ࡢ㛵ಀࠊసᴗဨࡢᑓ㛛ᛶ࡜ᩘࠊ

୺௵ࠊOPA࡜SPAࢆྠ୍㒊⨫࡜ࡋ࡚㐠Ⴀࡍࡿ⫼

ᬒᛮ᝿ࠊSCTODࡀOPA/SPA࡜ࢹ࣮ࢱࢆඹ᭷ࡍ

ࡿ௙⤌ࡳࠊྠ㸰⪅ࡣ㊥㞳ⓗ࡟ࡣ㞳ࢀ࡚࠸ࡿࡀࠊᐃ ᮇ఍ྜ➼ࢆᣢࡘࡢ࠿ࠊࡶࡋᝈ⪅ࡀࢹ࣮ࢱࢆせồࡋ ࡓ᫬┤᥋Ώࡍࡇ࡜ࡶ࠶ࡿࡢ࠿ࠊ୺἞་➼ࢆ௓ࡋ࡚

࠿ࠊ࢖㸧⡿ᅜෆ࡟ከᩘ࠶ࡿ⮖ᖏ⾑ࣂࣥࢡ࡜NMDP ࡢ㛵ಀࠊ࢘㸧⡿ᅜἲᚊࡢNMDP࡬ࡢᙳ㡪ࠋ どᐹࡣ◊✲༠ຊ⪅P Watlyࡢㄪᩚ࡟ࡼࡾ㸰᪥㛫

࡜࠸࠺▷ᮇ࡛ࡣ࠶ࡗࡓࡀᴟࡵ࡚ຠ⋡ⓗ࡟⾜ࢃࢀࠊ ከࡃࡢ᝟ሗࢆᚓࡿࡇ࡜ࡀฟ᮶ࡓࠋ௨ୗ࡟୺せ࡞ࡶ

ࡢࡢࡳグ㍕ࡍࡿ㸹 CIBMTR

CIBMTR࡟࠾࠸࡚࠾࠸࡚㸹

࢔㸧SCTODࡢࡓࡵࡢࢫ࣮࣌ࢫࠊసᴗ⪅ࡢᑓ㛛࡜

ேᩘ㸸༶ࡕ CIBMTR ࡢつᶍࠋChief Scientific Director ࡛࠶ࡿMary Horowitzࢆࢺࢵࣉ࡜ࡋ࡚

⤌⧊ᅗୖྡ๓ࡢ㍕ࡗ࡚࠸ࡿ࣓ࣥࣂ࣮ࡔࡅ࡛㸵㸯

ྡ࡛࠶ࡿࠋ࢖㸧ᑗ᮶௒ᅇࡢᡃࡀᅜࡢἲᚊ࡟ᇶ࡙࠸

࡚సࡽࢀࡓ♫ᅋἲே᪥ᮏ㐀⾑⣽⬊⛣᳜ࢹ࣮ࢱࢭ

ࣥࢱ࣮ࡀ┤࡟ࢥࣥࢱࢡࢺࡀྲྀࢀࡿせே㸸Mary Horowitz, Douglas Rizzoࠋ࢘㸧SCTOD㸦CIBMTR㸧

࡜NMDPཬࡧ௚ࡢࢹ࣮ࢱࢆᚲせ࡜ࡍࡿ⤌⧊㛫ࡢ ࢹ࣮ࢱ஺᥮ࡢ᪉ἲ㸦ఱ࠿ࣞࢠ࣮ࣗࣞࢩࣙࣥࡀᅾࡿ

࠿➼ࡶྵࡵ㸧㸸㸦௨ୗࡢNMDPࡢ㡯࡟グ㍕㸧 NMDP

NMDP࡟࠾࡟࠾࠸࡚࠸࡚㸹

࢔㸧The Office of Patient Advocacy/Single Point of Access (OPA/SPA)࡟ࡘ࠸࡚ࠊNMDP ࡜ࡢ㛵 ಀ㸸IT ࢩࢫࢸ࣒ࢆ NMDP ࡜ඹ᭷ࡍࡿࠊNMDP ෆࡢࢢ࣮ࣝࣉࠋ࢖㸧సᴗဨࡢᑓ㛛ᛶ࡜ᩘ㸸┳ㆤᖌ

㈨᱁ࢆ᭷ࡍࡿࡶࡢࠊࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮ࠊ◊✲⪅ే

ࡏ࡚ 20 ྡ௨ୖࡀ௙஦ࢆࡋ࡚࠸ࡿࠋ࢘㸧୺௵㸸 Elizabeth Murphy ࢚㸧OPA࡜SPAࢆྠ୍㒊

⨫࡜ࡋ࡚㐠Ⴀࡍࡿ⫼ᬒᛮ᝿: ࢥ࣮ࢹ࢕ࢿ࣮ࢺ࡜

࠸࠺సᴗࡀ୧⪅ࢆ⤖ࡧࡘࡅࡓࠋ࢜㸧SCTOD ࡀ

OPA/SPA ࡜ࢹ࣮ࢱࢆඹ᭷ࡍࡿ௙⤌ࡳ㸸SCTOD

ࡀࢹ࣮ࢱࢆసࡿࠋࡑࢀࢆᨻᗓࡢ࢙࢘ࣈࢧ࢖ࢺ࡟බ 㛤ࡍࡿࠋࡑࢀࢆOPA/SPAࡀᚲせ࡟ᛂࡌ࡚ຍᕤࡍ

ࡿࠋ࢝㸧ྠ㸰⪅ࡣ㊥㞳ⓗ࡟ࡣ㞳ࢀ࡚࠸ࡿࡀࠊᐃᮇ

఍ྜ➼ࢆᣢࡘࡢ࠿㸸ึᮇ࡟ࡣ㢖ᅇ࡟఍ྜࢆᣢࡗࡓ ࡀࠊ⌧ᅾ࡛ࡣ㛵㐃ࡍࡿᏛ఍࣭఍ྜࢆ฼⏝ࡍࡿࠋ㟁 ヰࠊ㟁Ꮚ፹య➼࡟ࡼࡿ㐃⤡ࡣ㢖ᅇ࡛࠶ࡿࠋ࢟㸧ࡶ

ࡋᝈ⪅ࡀࢹ࣮ࢱࢆせồࡋࡓ᫬┤᥋Ώࡍࡇ࡜ࡶ࠶

ࡿࡢ࠿ࠊ୺἞་➼ࢆ௓ࡋ࡚࠿㸸CIBMTR(SCTOD)

࡬ࡢᝈ⪅࠿ࡽࡢၥ࠸ྜࢃࡏࡣከࡃ࠶ࡿࡀࠊࡑࡢᵝ

࡞ ᫬ ࡟ ࡣ ୺ ἞ ་ ࢆ ௓ ࡋ ࡚ ࢹ ࣮ ࢱ ࢆ Ώ ࡍ ࠋ

CIBMTR ࡟୰࡟┤᥋ᝈ⪅ᑐᛂࢆࡍࡿᙺ๭࡟་ᖌ

ࡣ࠸࡞࠸ࠋࢡ㸧⡿ᅜෆ࡟ከᩘ࠶ࡿ⮖ᖏ⾑ࣂࣥࢡ࡜

NMDPࡢ㛵ಀ㸸㸦ἲᚊࡢᇶ࡙ࡁ୍ඖ໬୰࡛ࡣ࠶ࡿ

ࡀࠊᙉไࡣࡋ࡚࠸࡞࠸ࡼ࠺࡛࠶ࡿࠋ㸧ࢣ㸧⡿ᅜἲ ᚊࡢ NMDP ࡬ࡢᙳ㡪㸸㸦ಁ㐍࡜つไ཮᪉ࢆᐇឤ ࡋ࡚࠸ࡿࡼ࠺࡛࠶ࡗࡓࠋ㸧

㸶㸧Ḣᕞ

㸶㸧Ḣᕞ㦵㧊ࣂࣥࢡ㧊ࣂࣥࢡ㸦ⱥ⊂௖㸧ⱥ⊂௖㸧ࡢどᐹሗ࿌どᐹሗ࿌

㸦㈨ᩱᥦ౪㸸୕⏣ᮧ┿Ặ㸧

◊✲༠ຊ⪅ྡ࡟ࡼࡿḢᕞ㦵㧊ࣂࣥࢡࡢどᐹሗ࿌

ࢆᚓࡓࡢ࡛཰㘓ࡋ࡚࠾ࡃࠋ ๓ᩥ

඲ᅜ༠㆟఍࡛ࡣࠊ㐣ཤᖺ㛫࡟࠾ࡼࡪᝈ⪅ᨭ᥼ࠊ ࢻࢼ࣮ࣜࢡ࣮ࣝࢺάືࡢᐇໃ࡜ࠊ㛵㐃ㅖᅋయ࡜

ࡢ㐃ᦠࢆ㋃ࡲ࠼࡚᪂ἲ᪋⾜ᚋࡢࠊ┿࡟ᝈ⪅࡟࡜

ࡗ࡚᭷┈࡞㐀⾑⣽⬊⛣᳜་⒪⎔ቃࢆᩚഛࡍࡿࡓ

ࡵࡢཧ⪃࡜㈨ࡍࡿࡓࡵ࡟ࠊḢᕞඛ㐍ᅜࡢ㐀⾑⣽

⬊⛣᳜ࣂࣥࢡゼၥࢆ௻ᅗࡋࠊⱥᅜ㸦࢔ࣥࢯࢽ࣮

ࣀ࣮ࣛࣥ㈈ᅋ㸧ࠊࢻ࢖ࢶ㸦ZKRD㸧ࠊࣇࣛࣥࢫ 㸦FGM㸧࡜ࡢ㠃ㄯࢆ⤊࠼ࡓࡢ࡛ሗ࿌⮴ࡋࡲࡍࠋ

⥲ᣓ

㸯㸬኱ࡁ࡞ᡂຌࢆ཰ࡵ࡚࠸ࡿḢᕞ㸱࢝ᅜࡢ㐀⾑

⣽⬊ࣂࣥࢡ࡟ඹ㏻ࡍࡿ࣏࢖ࣥࢺࠊ≉ᚩࡣ௨ୗࡢ㸱

Ⅼ࡟㞟⣙ࡉࢀࡿࠋձ Web࡟ࡼࡿࢻࢼ࣮ᕼᮃ⪅ࡢ

࢜ࣥࣛ࢖ࣥⓏ㘓ไᗘࡢᑟධࠊࢻࢼ࣮DB࡬ࡢ᝟ሗ ࡢ⮬ື㌿㏦ࠊղၚᾮ᳨ᰝ࢟ࢵࢺ࡟ࡼࡿ DNA⡆

᫆ ᐃ࢟ࢵࢺ฼⏝࡟ࡼࡿᖜᗈ࠸ᒙ࡟ᑐࡍࡿࣜࢡ

࣮ࣝࢺάືࡢᒎ㛤ࠊճࢻࢼ࣮Ⓩ㘓ᖺ㱋ࡢపᖺ㱋

໬ಁ㐍ࠊ࡞ࡽࡧ࡟⏨ᛶࢻࢼ࣮ࡢ✚ᴟⓗⓏ㘓ࡢ᥎㐍 㸰㸬௒ᅇࠊ᪥ᮏ࡛ไᐃࡉࢀࡓࡼ࠺࡞͆⦡ࡾ͇࡜ࡶࠊ

͆ಁ㐍ἲ͇࡜ࡶゝ࠼ࡿ⛣᳜࡟㛵ࡍࡿᇶᮏἲࡣࠊᇶ ᮏⓗ࡟Ḣᕞ㸱࢝ᅜ࡟ࡣᏑᅾࡋ࡞࠸ࠋࡲࡓࠊࣞࢠࣗ

࣮ࣞࢩࣙࣥ࡜ࡋ࡚ࡢつไ࡜ࡶゝ࠼ࡿࠊ᪥ᮏ࡛ゝ࠺

8

࡜ࡇࢁࡢ⸆஦ἲ࡟㢮ࡍࡿἲࠊ࢞࢖ࢻࣛ࢖ࣥ࡞࡝ࡣ

୍㒊Ꮡᅾࡍࡿࡀࠊࡑࢀ࡛ࡶཎ๎ࠊ͆⛣᳜ࢆ᥎ዡࡍ

ࡿࡓࡵࡢ͇ᛶ㉁ࡢࡶࡢ࡛࠶ࡾࠊ᪥ᮏࡢࡼ࠺࡞つไ ἲ࡛ࡣ࡞࠸ࠋ

㸱㸬୍᪉࡛ࠊḢᕞ㸱࢝ᅜࡢࣂࣥࢡ⤌⧊ࡢ㐠Ⴀࠊ

஦ᴗ┠ᶆ࡞࡝ࡣࠊ᫂☜࡟ࢻࢼ࣮Ⓩ㘓ᣑ኱࡜ࠊ⛣᳜

ᶵ఍ᥦ౪࡜࠸࠺ほⅬ࡛࠶ࡾࠊᝈ⪅ᨭ᥼ࠊᡈ࠸ࡣࢻ ࢼ࣮ࣇ࢛࣮ࣟ࢔ࢵࣉ࡜ゝࡗࡓഃ㠃ࡣᐇ㉁Ꮡᅾࡋ

࡞࠸ࠋࡑࢀᨾࠊࡁࡵ⣽࠿࡞ᝈ⪅࠾ࡼࡧࢻࢼ࣮ࡢ ࢽ࣮ࢬࠊᏳ඲ᛶ࡟⪃៖ࡋࡓ᪥ᮏࡢᇶᮏࢫࢱࣥࢫ࡜

ࡣࡲࡗࡓࡃ␗࡞ࡿ≧ἣ࡛࠶ࡗࡓࠋ

㸲㸬ࡲࡓࠊ㸱࢝ᅜࡑࢀࡒࢀ㞄ྠᚿࡢᅜᐙ࡛࠶ࡿ

࡟ࡶ㛵ࢃࡽࡎࠊࡑࡢᅜẸᛶࡢ㐪࠸ࠊṔྐⓗ⫼ᬒ࡞

࡝࠿ࡽࡑࢀࡒࢀ⊂⮬ࡢ≉ᚩࢆ᭷ࡋ࡚࠸ࡿࡇ࡜ࡣ

⯆࿡῝࠸ࠋ

㸳㸬௒ᅇࠊ᪂ἲไᐃ࡟₈ࡂ╔ࡅࡓ᪥ᮏ࡛࠶ࡿࡀࠊ Ḣ⡿ࡢ㐀⾑⣽⬊ࣂࣥࢡ࡜ࡢẚ㍑࡛ࡣࠊ༢⣧࡟ຎࡗ

࡚࠸ࡿ࡜࠸࠺ᣓࡾ࡟࡞ࡿࡢ࡛ࡣ࡞ࡃࠊࡴࡋࢁ᪥ᮏ

ே≉᭷ࡢࡕᐦࡉࠊៅ㔜ࡉ࡞࡝ࡀⓎ᥹ࡉࢀ࡚ࡴࡋࢁ

ඛ㐍஦౛࡜࡞ࡗ࡚࠸ࡿ㡯┠ࡶᩓぢࡉࢀࡓࠋࡑࡢ ࡓࡵࠊ඲࡚ࢆᾏእࣂࣥࢡ࡟Ꮫࡪࡢ࡛ࡣ࡞ࡃࠊ᪥ᮏ ࡢᅜᅵࠊᅜẸẼ㉁࡞࡝࡟ྜ⮴ࡋࡓ⊂⮬ࡢࣂࣥࢡᵓ

᝿ࢆ⟇ᐃࡋ࡚ࡶࡼ࠸ࡢ࡛ࡣࠊ࡜࠸࠺༳㇟ࢆᣢࡗࡓࠋ ௨ୗ࡟ࠊどᐹࣂࣥࢡཬࡧᑐ㇟࡜ࡋ࡚ᡃࡀᅜࡢࠊ

ࣂࣥࢡྡࠊࢻࢼ࣮Ⓩ㘓⪅ᩘ࣭Ⓩ㘓ᖺ㱋ࠊ⤌⧊ᙧែ

ࢆグࡍ㸹$QWKR$QWKRQ\1RODQ7UXVW㸦ⱥᅜ㸧㸦ⱥᅜ㸧ࠊ⣙୓

ே࣭㹼ṓ㸦᪂つⓏ㘓㸧ࠊẸ㛫ᅋయࠊᨻᗓ⿵

ຓ㔠ࠊ=.5'=.5'㸦ࢻ࢖ࢶ㸧㸦ࢻ࢖ࢶ㸧ࠊ⣙୓ேࠊẸ㛫ᅋయࠊ )*0㸦ࣇࣛࣥࢫ㸧㸦ࣇࣛࣥࢫ㸧ࠊ⣙୓ே࣭㹼ṓࠊᨻᗓ ෆᶵ㛵ࠊJMDPJCBBN 㸦᪥ᮏ㸧⣙୓ே

㹼ṓබ┈ἲேࠊᨻᗓ⿵ຓ㔠 㸺ྛᅜゼၥグ㸼

㸯㸬ⱥᅜAnthony Nolan Trsut㸦ࣟࣥࢻࣥ໭

す㒊㸧

㠃ㄯ᪥᫬㸸ᖺ᭶᪥

㠃ㄯ⪅ 㸸 Richard Davidson, Director of Communications and Marketing

Ann O'Leary, Head of Register Development㸪 Manager of R&Be

ᴫせ

࣭⌧ᅾࠊࢻࢼ࣮Ⓩ㘓⪅ᩘ⣙୓ேࠋ᪥ᮏ࡜୎ᗘ

ྠつᶍࠋ⏨ᛶ⣙୓ேࠊዪᛶ୓ேࠋ┠ᶆ࡜

ࡍࡿࢻࢼ࣮ࣉ࣮ࣝࡣ୓ேࠋ≉࡟ࠊ HLAᏛⓗ

ぢᆅ࠿ࡽ♧ࡋ࡚࠸ࡿࡢ࡛ࡣ࡞ࡃࠊ࠶ࡃࡲ࡛ࡶᩘ್

┠ᶆ࡜ࡋ࡚タᐃࡋࡓࠋ࣭᪂つࡢࢻࢼ࣮Ⓩ㘓ᖺ㱋ࡣࠊ ௨๓ࡣṓ࠿ࡽṓࡲ࡛࡛࠶ࡗࡓࡀࠊࡇࡢ

᭶࠿ࡽṓࡲ࡛࡜ࡍࡿኚ᭦ࢆᐇ᪋ࡋࡓ㸦㸟㸧ࠋ ᐇ㝿࡟ᥦ౪ࢻࢼ࣮ࡢᖹᆒᖺ㱋ࡣṓ࡛࠶ࡿ࡜࠸

࠺࠿ࡽ㦫ࡁࡔࠋ⌧ᅾࡢⓏ㘓῭ࡳࢻࢼ࣮ࡢୡ௦ู

㢖ᗘ࡛࠸࠺࡜ࠊṓࡀࣆ࣮ࢡ࡛㸣ࢆ༨ࡵ

ࡿࠋ࣭ࢻࢼ࣮ᖺ㱋ࡢษࡾୗࡆࡣࠊ㡰ㄪ࡞ࢻࢼ࣮☜

ಖࡀᐇ⌧࡛ࡁ࡚࠸ࡿ⫼ᬒ࡜ྜࢃࡏ࡚ࠊࡸࡣࡾ⛣᳜

ᡂ⦼ࠊ୺἞་ഃ࠿ࡽࡢせᮃࡀࠊࠕⱝ࠸⏨ᛶࢻࢼ࣮

ࢆ㸟ࠖ࡜ࠊᑡࡋㄗゎࢆཷࡅ࠿ࡡ࡞࠸ᕼᮃࢆ⾲᫂

ࡍࡿࡓࡵࡢ᪋⟇ᐇ᪋ࡔ࡜࠸࠺ࠋࡑࡢᙳ㡪࡟ࡼࡾࠊ

௒ᖺᮎࡔࡅ࡛Ⓩ㘓᢯ᾘ࡜࡞ࡿࢻࢼ࣮Ⓩ㘓⪅㸦⌧

ṓ㸧ࡀே࡟ࡶཬࡪ࡜࠸࠺ࠋ௨㝆ࠊ࠿

ࡘ࡚ࡢୖ㝈ࡔࡗࡓṓࡢẁ㝵࡛⮬↛ῶ࡟ࡘ࡞ࡀ

ࡿ࡜࠸࠺ࠋᅉࡳ࡟࢖ࢠࣜࢫࡢ⊩⾑ᖺ㱋ࡣṓ࠿

ࡽṓࠋ࣭ࡉ࠸ᖏ⾑ࣂࣥࢡ࡟㛵ࡋ࡚ࡣࠊ㸲⑓㝔

ࣉࣛࢫNHS 㸦ⱥᅜཌ⏕┬㸧㸵ᶵ㛵࡛ಖᏑᐇ᪋ࠊ

⌧ᅾࠊಖᏑᩘࡀᑡ࡞࠸ࡀࠊᖺࡲ࡛࡟୓༓

ಖᏑࢆ┠ᣦࡋ࡚࠸ࡿ࡜࠸࠺ࠋ࣭ HLA᳨ᰝ᪉ᘧࡣ ᚑ᮶A, B, DP࡛࠶ࡗࡓࡀࠊᖺ࡟ධࡾ DQ

ࢆ㏣ຍࡋࠊ DNA㸲ࢣࢱ໬ࠋ⾑ΎᏛⓗ᳨ᰝ࠿ࡽ

ࡢ㌿᥮ࡣᖺ௦ึ㢌ࠋ࡜࠸࠺ࡇ࡜࡛ࠊࡸࡣࡾ

Ⓩ㘓ࢻࢼ࣮ࡢ኱༙ࡣ⾑Ύࢹ࣮ࢱࡢࡲࡲࡔࡀࠊ㏣ຍ

᳨ᰝ➼ࡣᐇ᪋ࡏࡎࠊ࠶ࡃࡲ࡛㐺ྜࡋ࡚࠿ࡽ෌᳨ᰝ CIBMTR࡟࠾࠸࡚

NMDP࡟࠾࠸࡚

㸶㸧Ḣᕞ㦵㧊ࣂࣥࢡ㸦ⱥ⊂௖㸧ࡢどᐹሗ࿌

ࡍࡿయไ࣭ HLAࡢศᕸ࡞ࡽࡧ࡟㐺ྜᗘ࠿ࡽゝ࠺

࡜ࠊ⌧ᅾ࡛ࡣⓏ㘓ᝈ⪅ࡢ⣙㸣࡟㐺ྜࢻࢼ࣮ࡣぢ ࡘ࠿ࡿࡽࡋ࠸ࠋ᪥ᮏࡀ⣙㸣࡜ㄝ᫂ࡍࡿ࡜㢔ࡁ ࡘࡘࡶࠊ⩎ࡲࡋ࠸࡜࠸࠺⾲᝟ࡔࡗࡓࠋ≉࡟ࠊぢ ࡘ࠿ࡽ࡞ሙྜࡢከࡃࡢ⌮⏤ࡣࠊࡸࡣࡾHLAࡢከ ᵝᛶ࡟౫Ꮡࡍࡿࡼ࠺࡛ࠊⓑⰍே✀௨እ࡟ࡶࠊ࢔ࣇ

ࣜ࢝⣔ࡢ⾑ᾮࡀὶࢀ࡚࠸ࡿࡇ࡜࠿ࡽࠊከᵝ࡞ศᕸ

ࢆ♧ࡍ࡜࠸࠺ࠋ࣭ࢻࢼ࣮ࣜࢡ࣮ࣝࢺάື࡟ࡼࡿࠊ

Ⓩ㘓⪅ࡢෆヂ࡛ࡣࠊ኱ูࡍࡿ࡜㸰✀㢮࡟ศࡅࡽࢀࠊ ࡍ࡞ࢃࡕ ANT ࡢࢫࢱࢵࣇ࣭࣮ࣜࢻ࡜࿧ࡤࢀࡿࠊ

⫋ဨࡀ㛵ಀᅋయ࡜༠ຊࡍࡿ࡞ࡾࡋ࡚ࠊᐇ㝿࡟ᡭࡀ ࡅࡿάືࡢ⤖ᯝࠊᚓࡽࢀࡿࢻࢼ࣮ࡢ☜ಖᩘࡀ Staff Leads ᱌௳ࠋ୰࡛ࡶࠊࡑࡢྡࡶࠕMarrowࠖ

࡜࿧ࡤࢀࡿ་Ꮫ⣔኱Ꮫ⏕୰ᚰࡢ⮬୺࣎ࣛࣥࢸ࢕

࢔࣭ࢧ࣮ࢡࣝ࡟ࡼࡿⓏ㘓఍ࡀ㸣࡛᭱ࡶከ࠸࡜࠸

࠺ࠋ Marrowࡣࠊᖺ௦ᚋ༙࡟Ⓨ㊊ࡋࠊ⌧ᅾ

ᅋయࠊṓ࠿ࡽṓࡲ࡛ࡢ㸱ᖺ㛫ࡢάືࠋ㸱 ᖺḟ࡟ࡣࠊேᮦ☜ಖࡋࠊᘬ㏥ࡍࡿ࡜࠸࠺ࠋୡ௦஺

௦ࡣ㡰ㄪ࡟᥎⛣ࡋ࡚࠸ࡿࠋḟ࠸࡛ࠊ㝣㌷࡟ࡼࡿ༠ ຊࡀ᭱ࡶ┒ࢇ࡛඲యࡢ⣙㸣ࠊࡉࡽ࡟ Patients Appeal࡜ゝ࠸ࠊ࠸ࢃࡺࡿᝈ⪅ࡉࢇ⮬㌟࡟ࡼࡿ㟢 ฟࠊᗈሗᡭẁ࡟ࡼࡿᙳ㡪ࡀ㸣㸦᪥ᮏ࡛ゝ࠺ࠊ

࠿ࡘ࡚ࡢ ACࡶ࠼ࡕࡷࢇ㸧ࠊ኱Ꮫ࡛ࡢⓏ㘓ࡀ 㸣࡜࡞ࡗ࡚࠸ࡿࠋ㸳␒┠࡜ࡋ࡚ࡣ࢖࣋ࣥࢺ㛵 㐃ࠋ࠿ࡽேつᶍࡢⱝ⪅ྥࡅࡢ࢖࣋ࣥࢺࠊ

≉࡟Music Festival ࡀ᭱ࡶຠᯝ࠶ࡾࡽࡋ࠸ࡀࡑ

ࢀ࡟ࡼࡿⓏ㘓ࡀ㏆ᖺቑຍഴྥ࡟࠶ࡿࠋ

NAVY/AirForce㸦ᾏ㌷✵㌷㸧࡟ࡼࡿ༠ຊࡶ᭱

㏆ጞࡵࡓࡤ࠿ࡾࠋ᭱㏆⬮ගࢆᾎࡧ࡚࠸ࡿࡢࡀࠊ R&Be࡜࠸࠺ࢢ࣮ࣝࣉ࡟ࡼࡿⓏ㘓άືࠋࡇࢀࡣࠊ

ࡶ࡜ࡶ࡜ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ࡟⯆࿡㛵ᚰࡀ࠶ࡗࡓ ᅋయࡀࠊ㦵㧊ࣂࣥࢡᨭ᥼࡟㉮ࡿࡼ࠺࡟࡞ࡗࡓ࡜࠸

࠺ࡇ࡜࡛ࠊ௒ᅇMtg࡛㠃ㄯࡋࡓAnnࡶࠊࡇࡢ R&Beᢸᙜࡢ࣐ࢿ࣮ࢪࣕ࡜࠸࠺⫪᭩ࢆᣢࡗ࡚࠸

ࡓࠋ୍࣭᪉ࠊMarketing Lead࡜࿧ࡤࢀࡿⓏ㘓 ᪉ᘧ࡛ࡣࠊᅽಽⓗ࡞๭ྜࡀࠊOnlineⓏ㘓ࠋࡘࡲ

ࡾࠊࢿࢵࢺⓏ㘓ࠋ Webࢧ࢖ࢺ࠿ࡽࡢ⏦ࡋ㎸ࡳ⪅

࡟ᑐࡋ࡚ࠊSpit Kitࢆ㒑㏦ࡍࡿࡇ࡜࡛ࡢⓏ㘓ࡀ

඲యࡢ㸣ࢆ༨ࡵࡿࠋၚᾮ᥇ྲྀ࢟ࢵࢺ㸦㸯ࢭࢵ

ࢺ㸵࣏ࣥࢻࠊ⣙෇㸧ࡣࠊࡇࢀ࡯࡝ᡭ㛫ࡀ࠿

࠿ࡽࡎ࡟Ⓩ㘓࡟ᐤ୚࡛ࡁࡿ᪉ἲࡶ࡞ࡃࠊ㠀ᖖ࡟ຠ

⋡ⓗ࡛≉࡟ⱝ࠸ୡ௦ࡢ⋓ᚓ࡟ᙺ❧ࡘ࡜࠸࠺ࠋ࣭ࢻ ࢼ࣮Ⓩ㘓࡟ᆅᇦไࠊ೫ᅾࡀ࠶ࡿࡢ࠿࡜⪺࠸ࡓ࡜ࡇ

ࢁࠊࣟࣥࢻࣥ࿘㎶ࡀ኱༙ࢆ༨ࡵࡿ࡜ᛮࢃࢀࡓࡀࠊ Ỵࡋ࡚ࡑ࠺࡛ࡣ࡞ࡃࠊ඲ᅵ࡟ศᕸࡋ࡚࠸ࡿ࡜࠸

࠺ࠋ࣭ᅉࡳ࡟ࠊⱥᅜ࡛ࡣᝈ⪅⮬㌟ࡀⓏሙࡋ✚ᴟⓗ

࡟࢔ࣆ࣮ࣝࡋ࡚࠸ࡿࡀ㸦ᅗ㸰ዪඣ෗┿㸧ࠊḢᕞ

ྛᅜ࡛ࡶࡑࡢࢫࢱࣥࢫࠊ⪃࠼᪉ࡀᵝࠎ࡛ࠊࢻ࢖

ࢶ࡛ࡣᐜㄆࡋ࡚࠸ࡿࡀࠊࡑࢀ࡯࡝✚ᴟⓗ࡛ࡣ࡞࠸ࠋ

୍᪉ࠊࣇࣛࣥࢫ࡛ࡣ Patients Appealࡣἲᚊ࡟

ࡼࡾ⚗ࡌࡽࢀ࡚࠸ࡿࠋణࡋࠊⱥᅜ࡛ࡶᵝࠎ࡞ᙳ 㡪ࠊᝈ⪅ࡉࢇࡢ≧ែࢆ⪃៖ࡋ࡚᭱㛗㸱ᖺ࡛㟢ฟࢆ

Ṇࡵ࡟ࡍࡿ࡜࠸࠺ࠋ࣭ᵝࠎ࡞Ⓩ㘓άື࡟࠾࠸࡚᥎ 㐍࡟ᐤ୚ࡋ࡚࠸ࡿࡢࡀࠊၚᾮ୰DNA᥇ྲྀ᪉ἲࠋ

࠿ࡘ࡚ࠊ NMDP㸦඲⡿㦵㧊ࣂࣥࢡ㸧࡞࡝࡛ࡣཱྀ

⭍ෆ⢓⭷᥇ྲྀ᪉ἲࢆ᥇⏝ࡋ࡚࠸ࡓࡀࠊ ANT࡛ࡣ

ࡼࡾ㐍໬ࠊ⡆౽໬ࡋࡓ࢟ࢵࢺࢆ᥇⏝ࠋࡇࡢ⡆᫆

࢟ࢵࢺࡀ࠶ࡿࡓࡵ࡟ࠊ୙≉ᐃከᩘࡀ㞟ࡲࡿ࢖࣋

ࣥࢺ➼࡛ࡢ୍ᩧⓏ㘓ࡀྍ⬟࡟࡞ࡿࠋHLA᳨ᰝ⢭

ᗘ࡟㛵ࡋ࡚ࡣࠊࡸࡣࡾ෌᳨ᰝࡢᚲせ࡞᳨యࡶ࠶ࡿ

࡜࠸࠺ࠋࡇࢀࡣࠊ༑ศ࡞ DNA㔞ࢆ᥇ྲྀ࡛ࡁ࡞

࠿ࡗࡓሙྜ࡟㉳ࡇࡿ࡜࠸࠺ࠋ࣭ㄢ㢟࡜ࡋ࡚ࡣࠊຠ

⋡㏣ồ࡜ࠊࢥࢫࢺ๐ῶࠋၚᾮ᥇ྲྀ࢟ࢵࢺࡢ↓㥏࡛

⤊ࢃࡗ࡚࠸ࡿ࢟ࢵࢺࡢపῶ࡬ࠋ࣭ࣈࣛࣥࢻ࢖࣓࣮

ࢪ࡜ࡋ࡚ࡣࠊ௨๓ࡣࠕⰼࠖࢆࢸ࣮࣐࡟ࡋ࡚ࣟࢦ

ࢆ౑⏝ࡋ࡚࠸ࡓࡀࠊᖺ࠿ࡽࢥࣥࢧࣝࢱࣥࢺ

ࢆධࢀ࡚ CI㸦Corporate Identity㸧ࢆ᳨ウࡋࠊ

⌧ᅾࡢ㯮࡜⥳ࢆᇶㄪ࡜ࡋࡓ࢖࣓࣮ࢪ࣮࢝ࣛ࡟ኚ

10

᭦ࠋ࣭ ANT ࡢ㐠Ⴀࠊᇶᮏ᪉㔪࡜࡞ࡿ࢞࢖ࢻࣛ࢖

ࣥࠊἲ࡞࡝ࡀᏑᅾࡍࡿ࠿࡜☜ㄆࡋࡓࡽࠊࡲࡎࡣ WMDA Standard࡟‽ᣐࡋ࡚࠸ࡿ࡜࠸࠺ࡇ࡜ࡔ ࡀࠊ௚࡟ࡣⱥᅜෆࡢHTA, Human Tissue Authority࡜࠸࠺⤌⧊ࡀࠊࣄࢺ⣽⬊ࢆ⏝࠸ࡓ⛣᳜

࡟㛵ࡍࡿྜពᩥ᭩ࠊ࡜࠸ࡗࡓෆᐜࡀ࠶ࡾࠊࡇࢀ

ࡽ࡟‽ᣐࡋ࡚࠸ࡿࡀࠊ࠸ࡎࢀ࡟ࡋ࡚ࡶཝࡋ࠸ࣞࢠ

࣮ࣗࣞࢩ࡛ࣙࣥࡣ࡞࠸࡜࠸࠺ࠋ࣭Patients Adovocate㸦ᝈ⪅᧦ㆤ㸧࡟㛵ࡋ࡚ࡣࠊ⌧᫬Ⅼ࡛

ࡣࡲࡗࡓࡃ࢔ࢡࢩࣙࣥࡀ࡞࠸ࠋࡏࡵ࡚Patients Appeal࡜࠸࠺㛵㐃࡛ࠊᝈ⪅ࡀᬑཬၨⓎ࡟࢔ࣆ࣮

ࣝࡍࡿࡓࡵࡢάື࡟ᝈ⪅ࢆ㉳⏝ࡍࡿ⛬ᗘ࡜࠸࠺ࠋ ణࡋࠊANTࡢෆ㒊࡛ࡶࠊᝈ⪅ᨭ᥼ࡢάືࡶྠ᫬

࡟ᐇ᪋ࡋ࡞࠸࡜୙༑ศ࡛࠶ࡿ࡜࠸࠺ㄆ㆑ࡣ᭱㏆

ฟጞࡵ࡚࠸ࡿ࡜࠸࠺ࠋ࣭ᅉࡳ࡟ࠊ࢔ࣥࢯࢽ࣮㸦ᝈ ඣ㸧ࡢẕぶࡢࢩࣕ࢖࣮࣭ࣜࣀ࣮ࣛࣥࡣࠊ㸳ᖺ๓࡟

Ṛཤࠋ⌧ᅾࠊ୍㒊ࡢ⌮஦ࡀᐙ᪘࡜ࢥࣥࢱࢡࢺࢆྲྀ

ࡗ࡚࠸ࡿࡀࠊ஦ᴗ࡟ࡣ୍ษ㛵▱ࡋ࡚࠸࡞࠸࡜࠸࠺ࠋ

ࡲࡓࠊබⓗ㦵㧊ࣂࣥࢡ࡛࠶ࡿ࡟ࡶ㛵ࢃࡽࡎࠊಶே

ྡࠊᅛ᭷ྡモ࡛࠸ࡘࡲ࡛ࡶࣂࣥࢡࡢྡ⛠ࡀṧᏑࡋ

࡚࠸ࡿࡇ࡜ࡀၥ㢟↓࠸࠿ࠊ☜ㄆࡋࡓ࡜ࡇࢁࠊ☜࠿

࡟ዲࡲࡋࡃ࡞࠸ࠊ࡜࠸࠺ពぢࡶ࠶ࡿ୍᪉ࠊ௒ࡉ

ࡽኚ᭦࡛ࡁ࡞࠸࡜࠸࠺⫧኱໬ࡋࡓ⤌⧊ࡀᢪ࠼ࡿ

ㄢ㢟࡟┤㠃ࡋ࡚࠸ࡿࡼ࠺ࡔࡗࡓࠋ

㸰㸬ࢻ࢖ࢶ ZKRD; Zentrales

Knochenmarkspender-Register Deutschland 㸦࣒࢘ࣝᕷ㸧

㠃ㄯ᪥᫬㸸ᖺ᭶᪥

㠃ㄯ⪅㸸Hans-Peter Eberhard,PhD, Head of Search and Transplant Services

࣭ ZKRD 㸦ࢻ࢖ࢶ㦵㧊୰ኸࣂࣥࢡ㸧ࡢᡤᅾᆅ ࡣࠊࢻ࢖ࢶ༡㒊ࡢᑠ㒔ᕷ࣒࢘ࣝᕷ࡟఩⨨ࡍࡿࠋ୎

ᗘࠊ࣑ࣗࣥ࣊ࣥ࡜ࢩࣗࢶࢵࢺ࢞ࣝࢺࡢ୰㛫Ⅼ㎶

ࡾࠋ࣭ZKRDࡣࠊ၏୍ࡢබⓗ㦵㧊ࣂࣥࢡࠋᨻ

ᗓ࠿ࡽࡢ⿵ຓ㔠➼ࡣ୍ษཷࡅ࡚࠸࡞࠸ࠊ᏶඲࡟⊂

❧ࡋࡓࣂࣥࢡ⤌⧊ࠋࡼࡗ࡚ࠊἲⓗつไࡶ࢞࢖ࢻ

ࣛ࢖ࣥ➼ࡶ≉࡟Ꮡᅾࡋ࡞࠸ࠋ࣭་⒪ಖ㝤࡟ࡘ࠸

࡚ࡶࠊ▷ᮇධ㝔ࠊ㛗ᮇධ㝔࡛␗࡞ࡿࡀࠊ࠸ࡎࢀ

࡟ࡋ࡚ࡶᝈ⪅ࡢ⤒῭஦᝟࡟ࡼࡗ࡚ᨭᡶࡀࡿࠊ୙

᫂࡞ࡼ࠺࡟࡞ࡽ࡞࠸ࡼ࠺࡟♫఍ࡢࢭ࣮ࣇࢸ࢕ࢿ

ࢵࢺࡣᏑᅾࡋ࡚࠸ࡿࠋලయⓗ࡟ࡣࠊ་⒪㈝ࡢᨭᡶ

࠸ࡀᖺ㛫ᡤᚓࡢ㸣ࢆ㉸࠼࡚ࡣ࡞ࡽ࡞࠸ࠊ⦡ࡾࠊ

ୖ㝈ࡀ࠶ࡿࠋ࣭ZKRDࡢ⌧ᅾࡢࢻࢼ࣮ᩘࣥᐇ⦼

ࡣ⣙୓ேࠋࡊࡗ࡜᪥ᮏࡢಸࠋ࡞ࡐࠊࡇࢀ࡯

࡝ࡲ࡛࡟ᡂ㛗ࠊᡂຌࡋࡓࡢ࠿࡜☜ㄆࡋࡓ࡜ࡇࢁࠊ ᗄࡘ࠿ࡢ⌮⏤ࡣぢᙜࡓࡿࡶࡢࡢࠊࠕ⮬↛࡟ࡑ࠺࡞

ࡗࡓࠖࠊ࡜࠸࠺ࢥ࣓ࣥࢺࡀᖐࡗ࡚ࡁࡓࠋ࣭ ZKRD ࡢᮏ㒊ࡀࠊࢻ࢖ࢶ༡㒊ࡢᑠ㒔ᕷ࣒࢘ࣝ࡟Ỵࡲࡗࡓ

⤒⦋࡟ࡘ࠸࡚ᑜࡡࡿ࡜ࠊᨻᗓࡀᙜึ୰ኸࣂࣥࢡࡢ බເࢆᖺ㡭࡟ᐇ᪋ࡋࡓ㝿ࠊ㸱࠿ᡤࡢࣂࣥࢡ ẕయࡀᡭୖࡆࢆࡋࡓ࡜࠸࠺ࠋࡑࢀࡣࠊ࢚ࢵࢭࣥࠊ ࢻࣞࢫࢹࣥࠊ࣒࢘ࣝࡀྡ஌ࡾࢆ࠶ࡆࡓࡽࡋ࠸ࠋᙜ

᫬࣋ࣝࣜࣥࡣࠊ࣋ࣝࣜࣥࡢቨᔂቯ࡛ᮾす෭ᡓ㞷ゎ ࡅࡢ᫬ᮇ࡛࠶ࡗࡓࡓࡵ࡟ࠊΰ஘ࢆᴟࡵ࡚࠾ࡾぢ㏦

ࡽࢀࡓࠋࡲࡓࠊ௚ࡢೃ⿵㒔ᕷ࡜ࡢ຾㈇࡛ࡣ᭷ຊ

࡞኱ᏛᩍᤵࡀᏑᅾࡋ࡚࠸ࡓࡇ࡜ࠊ᪤࡟኱Ꮫࢆ୰ᚰ

࡜ࡋࡓᆅᇦࣂࣥࢡ࡛ࡢᐇ⦼ࡀ࠶ࡗࡓࡇ࡜࡞࡝࠿

ࡽ᭱⤊ⓗ࡟࣒࢘ࣝࡀᙜ☜࡜࡞ࡗࡓࠋ࣭⌧ᅾࡢࣂࣥ

ࢡ⤌⧊ࡢᵓᡂ࡜ࡋ࡚ࡣࠊࢻࢼ࣮ࢭࣥࢱ࣮ࡀ࠿

ᡤࠊ᥇ྲྀࢭࣥࢱ࣮ࡀ࠿ᡤࠊ⛣᳜ࢭࣥࢱ࣮ࡀ

࠿ᡤ㸦ᡂே࣭ᑠඣู㸧ࢧ࣮ࢳࢭࣥࢱ࣮ࡀ࠿ᡤ

࠶ࡿࠋ㸦⛣᳜࡜ࢧ࣮ࢳC ࡣู㸧࣭ᙺဨࡣࠊCEO㸰

ྡไࠋ୍ேࡣ⣧↛ࡓࡿࣅࢪࢿࢫ⤒㦂⪅ࠊࡶ࠺୍ே

ࡣMedical Director࡜࠸࠺⛠ྕࠋ௒ᅇࠊ࠾ୡヰ࡟

࡞ࡗࡓ Hans-PeterࡣࠊHead of Search Transplant Services࡜࠸࠺ࡇ࡜࡛ࠊࢥ࣮ࢹ࢕ࢿ

࣮ࢺࠊ⛣᳜ㄪᩚ࡞࡝ࢆྵࡴ⥲ᣓⓗ㒊⨫ࡢ㈐௵⪅࡛

࠶ࡾࠊᐇ㉁㐠Ⴀ㒊㛛ࡢ᭱㧗㈐௵⪅࡜ゝ࠼ࡿࠋ࣭

࠸ࢃࡺࡿࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮άືࢆ⾜࠺ᢸᙜ⪅ࡣ

ேࠋࡇࡢ࣓ࣥࣂ࣮ࡣࠊ DRK㸦Deutsch Red Kross㸧ࢻ࢖ࢶ㉥༑Ꮠ♫ࠋ࣭ OnlineⓏ㘓ࡣࠊ ZKRD⮬㌟ࡣᐇ᪋ࡋ࡚࠸࡞࠸ࡀࠊྛDC㸦ࢻࢼ࣮

ࢭࣥࢱ࣮㸧࡛ࣞ࣋ࣝᐇ᪋ࡉࢀ࡚࠸ࡿࠋ࣋ࣝࣜࣥࡢ DKMS࡞࡝ࠋࡸࡣࡾࠊၚᾮ᥇ྲ᳨ྀᰝ᪉ᘧࡢ᥇⏝

࡜ࢭࢵࢺ࡛ࠋDC࠿ࡽࡣࠊࢻࢼ࣮᝟ሗࡀ㸯㐌㛫࡛

ᒆࡁࠊࢧ࣮ࢳࡀጞࡲࡿࠋ࣭᭱㏆ヰ㢟࡟࡞ࡗࡓ኱つ ᶍ࡞࢖࣋ࣥࢺ࡜ࡋ࡚ࡣࠊࠕ࣑࣭ࣗࣥ࣊ࣥࣈ࣮ࣞࢻ ࢼ࢖ࢺࠖ࡜࠸࠺ࡶࡢ࡟᪂ࡋࡃ༠㈶ࡋࡓࠊࡇࢀࡣ

࣑ࣗࣥ࣊ࣥᕷෆࡢ㏻ࡾࢆࠊṌ⾜⪅ኳᅜ࡜ࡋࡓ࣮ࣟ

࣮ࣛࢫࢣ࣮ࢺࡢ࢖࣋ࣥࢺ࡛ࡸࡣࡾⱝᖺ⪅ᒙ࡬ࡢ

࢔ࣆ࣮ࣝࡢᶵ఍࡟࡞ࡗࡓ࡜࠸࠺ࠋ࣭⛣᳜ᝈ⪅࡜ࢻ ࢼ࣮࡜ࡢᑐ㠃࡟ࡘ࠸࡚ࡣࠊ㸰ᖺᚋ࡟཮᪉ࡀ఍࠸ࡓ

࠸࡜ᕼᮃࡋࡓሙྜࠊᙜ஦⪅㛫࡛ࡢỴᐃ࡟௵ࡏࡿ࡜

࠸࠺ࡶࡢࠋ࠾ࡼࡑ⛣᳜࣌࢔ࡢ㸲⤌࡟㸯⤌ࡀఱࡽ࠿

ࡢᑐ㠃ࢆᐇ⌧ࡋ࡚࠸ࡿ࡜࠸࠺ࠋグ⪅఍ぢࢆࡍࡿ

ሙྜࡶࠊᘧ඾࡛ࡢሙྜࡶࠋ᪥ᮏ࡛ࡣࢿ࢞ࢸ࢕ࣈ࡞

᝿ᐃ࠿ࡽ୓୍ࡢࢺࣛࣈࣝࢆᠱᛕࡍࡿពぢࡀ࠸ࡲ

ࡔከᩘࢆࡋࡵࡿࠋࡑࡇ࡛ࠊ࠿ࡘ࡚ᐇ㝿࡟ࢺࣛࣈࣝ

ࡀⓎ⏕ࡋࡓ஦౛ࢆ⪺࠸ࡓࡀࠊࢻ࢖ࢶᅜෆ࡛ࡣ⪺࠸

࡚࠾ࡽࡎࠊࢫ࢖ࢫ࡛㔠㖹ᤵཷࡢၥ㢟ࡀⓎ⏕ࡋ࡚௨ ᮶⚗Ṇࡋ࡚࠸ࡿ࡜࠸࠺ࠋ

㸱㸬ࣇࣛࣥࢫ FGM France Greffe de Moelle 㸦ࣃࣜᕷ໭㒊㸧

㠃ㄯ᪥᫬㸸ᖺ᭶᪥

㠃ㄯ⪅㸸Dr.Francoise Audat, Donor’s Department, Director, Physician,

GFM Registry Dept. Operations Medical Chief Officer, Agence De La Biomedecine

࣭ࣇࣛࣥࢫࡢ㦵㧊ࣂࣥࢡࡣࠊ᏶඲࡟ᅜࡢᶵ㛵ࡢ୍

㒊ࠋ௖ཌ⏕┬ࣅࣝෆ࡟ࠊ㸱ࡘࡢ⤌⧊ࡀඹᏑ࣭

France Greffede Moelle ࡣ┤ヂࡍࡿ࡜ࣇࣛࣥࢫ

⛣᳜࣭㦵㧊ᶵ㛵ࠋ⫋ဨேࠋࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮

⣙ே⛣᳜᪋タ⣙ᶵ㛵ࠋ࣭ࢻࢼ࣮Ⓩ㘓⪅ᩘ

⣙୓ேࠊࢻࢼ࣮ᖺ㱋ṓ௨ୗ࣭㠀⾑⦕⛣᳜ᖺ 㛫౛ࠊ⾑⦕ࡶྵࡵࡿ࡜ࠊ㦵㧊⛣᳜౛ࠊ PB,CBࡣࡑࢀࡒࢀ౛࣭ၚᾮ᳨ᰝ᪉ᘧࡣࠊࣇࣛ

ࣥࢫࡶᐇ᪋ࠋྠ᳨ᰝ᪉ᘧࢆᐇ᪋ࡍࡿᅜ࡜ࡋ࡚ࡣ෌

᳨ᰝ⋡࡜ࡋ࡚ࠊⱥࠊ⊂ࠊࢫ࢖ࢫࠊ US࡞࡝㸣௨

ୗ࡜ࡉࢀ࡚࠸ࡿࡀࠊ௖࡛ࡣ⛬ᗘࠋ⢭ᗘࡣࠊ

DNA㔞ࡀ㊊ࡾ࡞࠸࡜ᚲせ࡟࡞ࡿࠋ࣭ PB࡜ BM

ࡢ㑅ᢥࠋ᭱ึࡣᝈ⪅ഃࠊࢻࢼ࣮࡟⾑ᰦ⑕ࡀ࠶ࢀࡤ PBࢆ㑅ᢥࡍࡿࡇ࡜ࡀ࠶ࡿࠋࢻ࢖ࢶࡣPBẚ⋡㧗

࠸ࠋ࣭௖ࡢ㐀⾑⣽⬊ࡢᥦ౪ࡣ㦵㧊ࠊᮎᲈ⾑ࠊ DLI

ྵࡵ࡚㸰ᅇࡲ࡛ࡔࡀࠊࡑࢀࡶྠ୍ࡢᝈ⪅ࡔࡅ࡜࠸

࠺ࠋఱᨾࡇ࠺ࡋࡓ⦡ࡾࡀ࠶ࡿࡢ࠿㈐௵⪅ࡶ୙ྍ

ゎ࣭⤫ィゎᯒࡢᑓ㛛ᐙࢆ⫋ဨ࡟ᢪ࠼࡚࠸࡚ࠊᖺሗ

ࢆⓎ⾜ࡋ࡚࠸ࡿࠋ་ᖌ࡜ࡢ㐃ᦠࢆᖖ࡟ྲྀࡾࠊᏛ

఍Ⓨ⾲࡞࡝ࡶFGM࡜ࡋ࡚ࡶ✚ᴟⓗ࡟⾜ࡗ࡚࠸

ࡿࠋᝈ⪅࡜ࢻࢼ࣮ࡢᑐ㠃࡟㛵ࡋ࡚ࡣࠊFGMࡢ᪉ 㔪࡜ࡋ࡚ࠕ⚗Ṇࠖࡋ࡚࠸ࡿࠋ⌮⏤࡟ࡘ࠸࡚ࡣࠊ⫋

ဨࡢ㛫࡛ࡶࡼࡃ⌮ゎࡋ࡚࠸࡞࠸࣭͆Ce aue tu Donnes aux autres, tule Donnes A toi-meme͇

࢔ࣇࣜ࢝ࡢࡇ࡜ࢃࡊࠕ࠶࡞ࡓࡀ୚࠼ࡓࡢ࡜ྠࡌࡶ

ࡢࢆࠊ࠶࡞ࡓࡣ୚࠼ࡽࢀࡿࡢ࡛ࡍࠖࡇࡢ࣓ࢵࢭ࣮

ࢪࡀグ㍕ࡉࢀࡓࡋ࠾ࡾࢆࠊThank you Letter࡜

୍⥴࡟᥇ྲྀᚋࡢࢻࢼ࣮࡟ࠊグᛕရࡢ◁᫬ィ࡜୍⥴

࡟ࢻࢼ࣮࡟ࣉࣞࢮࣥࢺࡋ࡚࠸ࡿࠋ

䠕䠅㼃㻴㻻䛾ືྥ䠖㻌 䠕䠅㼃㻴㻻䛾ືྥ䠖㻌

WHOࡣ㐀⾑ᖿ⣽⬊⛣᳜㛵㐃ἲ᱌ࡢᇶᮏⓗ⪃࠼ࡸ

ἲ᱌ࡀᑐ㇟࡜ࡍ࡭ࡁ㡿ᇦ➼࡟ࡘࡁࠊ ㏆ᖺ୍ᐃࡢ ぢゎࢆฟࡋࡘࡘ࠶ࡿࠋ༶ࡕࠊWHO ࡣࠊWHO GUIDING PRINCIPLES ON HUMAN CELL, TISSUE AND ORGAN TRANSPLANTATION 㸦The sixty-third World Health Assembly in May 2010㸧࡟࠾࠸࡚ࠊ⮚ჾࠊ⤌⧊ࠊ⣽⬊㸦ࡇࡇ࡟㐀⾑

12

ᖿ⣽⬊ࡀྵࡲࢀࡿ㸧⛣᳜࣭ᥦ౪࡟㝿ࡋࠊ͆⤯࠼ࡊ

ࡿ㆙ᡄ࡜┘どVigilance and surveillance͇ࡀ ᚲせ࡛࠶ࡿ᪨グ㍕ࡋࡓࢃࡅ࡛࠶ࡿࡀࠊᡃࡀᅜࠊ

APBMTࠊWBMTࡀࡇࢀࡲ࡛ࡶ⾜ࡗ࡚ࡁࡓ㐀⾑ᖿ

⣽⬊⛣᳜ୡ⏺ㄪᰝཬࡧࡇࢀ࠿ࡽグࡍᝈ⪅ࠊࢻࢼ࣮

ࡢ࢔࢘ࢺ࣒࢝ࣞࢪࢫࢺࣜ㸦⛣᳜࣭ᥦ౪౛࡟࠾ࡅࡿ

ணᚋㄪᰝ㸧ࡣࠊࡇࡢ㆙ᡄ࡜┘どࡢල⌧໬࡜ࡋ࡚௚

ࡢ㡿ᇦࡢࣔࢹࣝ࡜┠ࡉࢀ࡚࠸ࡿࠋ

ᝈ⪅䞉䝗䝘䞊䛾Ᏻ඲ᛶ䜔⮫ᗋᡂ⦼䛻㛵䛩䜛䝕䞊䝍䛾䚸㻌 ᝈ⪅䞉䝗䝘䞊䛾Ᏻ඲ᛶ䜔⮫ᗋᡂ⦼䛻㛵䛩䜛䝕䞊䝍䛾䚸㻌 ୡ⏺つᶍ

ୡ⏺つᶍ䛷䛾㞟ィ䛸ゎ䛷䛾㞟ィ䛸ゎᯒ㻌

㸯㸧ᝈ⪅ࡢᏳ඲ᛶ୪ࡧ࡟⮫ᗋᡂ⦼ࡢୡ⏺つᶍ࡛ࡢ 㞟ィ࡜ゎᯒ࡟㛵ࡋ࡚࡛࠶ࡿࡀࠊ㞟ィ࡟㛵ࡋ࡚ࡣඛ

㏙ࡢୡ⏺ࢧ࣮࣋࢖࡟グࡋࡓࠋゎᯒࡣࡼࡾヲ⣽࡞ࢹ

࣮ࢱࢆ㞟ࡵࡿᚲせࡀ࠶ࡾࠊࡑࢀࡀᝈ⪅࢔࢘ࢺ࣒࢝

ࣞࢪࢫࢺ࡛ࣜ࠶ࡿࡀࠊAPBMT, CIBMTR, EBMT ࡣWBMTෆࡢ୕኱ᝈ⪅࢔࢘ࢺ࣒࢝ࣞࢪࢫࢺࣜࡢ ᶵᵓ࡛࠶ࡿࠋࡇࡢ୕ࡘࡢࣞࢪࢫࢺ࡛ࣜ㞟⣙ࡍࡿᝈ

⪅᝟ሗࡢෆඹ㏻㡯┠ࢆLeast Minimum Dataset

࡜ࡋ࡚タᐃࠊ2012ᖺᗘ࡟ึࡵ࡚ඛⓎࡢCIBMTR, EBMT ࡜ྠࡌᇶ‽࡛࢔ࢪ࢔࣭ኴᖹὒᆅᇦ࡟࠾ࡅ

ࡿ㐀⾑ᖿ⣽⬊⛣᳜඲యࡢ⛣᳜ᚋ⏕Ꮡ᭤⥺ࢆసᡂ ࡋࠊࡇࡢᆅᇦࡢᡂ⦼ࡀCIBMTR, EBMTࡢࡑࢀ

࡜ẚ࡭ࠊ㐯Ⰽ࡞࠸ࡇ࡜ࢆ♧ࡋࡓࠋ

㸰㸧㐀⾑ᖿ⣽⬊ࢻࢼ࣮ࡢᏳ඲ᛶ࡟㛵ࡋ࡚ࡣࠊ WBMTࡢᵓᡂ࣓ࣥࣂ࣮ࡢ୍ࡘ࡛࠶ࡿWMDAࡀ 㠀⾑⦕࣎ࣛࣥࢸ࢕࢔ࢻࢼ࣮୪ࡧ࡟⮖ᖏ⾑࡟㛵ࢃ

ࡿᏳ඲᝟ሗࢆᤕᤊ࣭ୡ⏺ⓎಙࡍࡿSEAR (Severe Event and Adverse Reactions), SPEAR (Severe Product Event and Adverse Reactions)࡜࿧ࡤ

ࢀࡿ௙⤌ࡳࢆᵓ⠏ࡋ࡚࠸ࡿࠋᡃࡀᅜ࡛ࡣࠊ2000 ᖺ4᭶࠿ࡽ⾑⦕ᮎᲈ⾑ᖿ⣽⬊ࢻࢼ࣮ࡢࠊ2005ᖺ 4᭶࠿ࡽࡣ⾑⦕㦵㧊࣭ᮎᲈ⾑ᖿ⣽⬊ࢻࢼ࣮ࡢ඲௳

஦๓Ⓩ㘓࣭ࣇ࢛࣮ࣟ࢔ࢵࣉ஦ᴗࢆᐇ᪋ࡋ࡚࠾ࡾࠊ

⾑⦕ࢻࢼ࣮ࡢᏳ඲ᛶ࡟ࡶ╔┠ࡋࡓࡇ࡜ࡣୡ⏺ⓗ

࡟ࡶホ౯ࡉࢀࡘࡘ࠶ࡿࠋ㦵㧊ࣂࣥࢡ࡛ࡶ1991ᖺ

Ⓨ㊊ᙜึࡼࡾ㠀⾑⦕ࢻࢼ࣮ࡢᏳ඲᝟ሗࢆᤕᤊࡋ

࡚࠸ࡿࠋࡇ࠺ࡋࡓ⾑⦕࣭㠀⾑⦕ࢻࢼ࣮୪ࡧ࡟⮖ᖏ

⾑ࡢᏳ඲ᛶ࡟㛵ࡍࡿୡ⏺ⓗ࡞ὀ┠ࡢ㧗ࡲࡾࡢ୰

࡛ࠊWBMTࡣ2012ᖺᗘ࡟ࠊྠ✀㐀⾑ᖿ⣽⬊ᥦ ౪࡟㛵ࡍࡿWBMTࡢ⤫୍ぢゎ ”Allogeneic hematopoietic stem cell

donation :standardized assessment of donor outcome data-A WBMT consensus document.

Bone Marrow Transplant 2012, 1-6”ࢆⓎ⾲ࡋ ࡓࠋࡇࡢ୰࡟ࡣ⾑⦕ࠊ㠀⾑⦕ࢆၥࢃࡎᖿ⣽⬊ᥦ౪

┤ᚋ࡟ሗ࿌ࡉࢀࡿ࡭ࡁ㡯┠ࠊ㛗ᮇࣇ࢛࣮ࣟ࢔ࢵࣉ

࡛ሗ࿌ࡉࢀࡿ࡭ࡁ㡯┠ࡀグ㍕ࡉࢀ࡚࠸ࡿࠋ

ࠕ⛣

ࠕ⛣᳜࡟⏝࠸ࡿ᳜࡟⏝࠸ࡿ㐀⾑ᖿ⣽⬊㐀⾑ᖿ⣽⬊ࡢ㐺ษ࡞ᥦ౪ࡢ㐺ษ࡞ᥦ౪ࡢ᥎㐍ࡢ᥎㐍

࡟㛵ࡍࡿ

࡟㛵ࡍࡿἲᚊࠖཬࡧᚊࠖཬࡧࠕྠἲ⋡ᴫྠἲ⋡ᴫせࠖࡢⱥヂࠖࡢⱥヂ ᅜ㝿᝟ሗ཰㞟ࢆࡍࡿୖ࡛ࡣࠊᮏ◊✲ࡢ⫼ᬒ༶ࡕୖ

グἲᚊࢆ⌮ゎࡋ࡚ࡶࡽ࠺ࡇ࡜ࡀᚲせ࡛࠶ࡿࡢ࡛ࠊ ⱥヂࢆᮏ◊✲ࡢ୍⎔࡜ࡋ࡚⾜࠸ࠊᅜෆእ࡟㓄ᕸࡍ

ࡿ࡜࡜ࡶ࡟ࠊ᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍࣮࣒࣮࣍࣌ࢪ

ୖ࡟㛤♧ࡋࡓࠋ

㹂㸬⪃ᐹ

1㸧APBMT/WBMT/WHOࢆ௓ࡋࡓࠊ㐀⾑⣽⬊⛣

᳜࡟㛵ࢃࡿ᝟ሗ཰㞟࡟㛵ࡋ࡚ࡣࠊWBMTࡢࡑࢀ

ࡲ࡛ࡢ㐀⾑⣽⬊⛣᳜ୡ⏺ࢧ࣮࣋࢖࡟ຍ࠼ࠊྠᶵᵓ

࡜ࡋ࡚ึࡵ࡚ࡢୡ⏺࢔ࣥࢣ࣮ࢺࢆᐇ᪋ࠊⓎ㏦ඛࡀ ୡ⏺࡯ࡰࡍ࡭࡚ࡢᆅᇦ࡟ཬࢇࡔࡇ࡜ࠊᅇ⟅⋡ࡣ࡜

ࡶ࠿ࡃࡶ୍ࡘࡢ㡿ᇦ࡟࠾ࡅࡿୡ⏺࡛ࣞ࣋ࣝࡢẚ

㍑ⓗ㎿㏿࡞᝟ሗ཰㞟ࡢ௙⤌ࡳࡀసືࡍࡿࡇ࡜ࡀ

☜ㄆ࡛ࡁࡓࡇ࡜ࡣࠊᮏ◊✲ࡀୡ⏺࡛ࣞ࣋ࣝホ౯ࡉ

ࢀ࡚ࡶⰋ࠸኱ࡁ࡞ᡂᯝ࡛࠶ࡗࡓ࡜⪃࠼ࡿࠋࡇࠋࡑ ࡋ࡚࢔ࢪ࢔ࢆྵࡵࡓㅖእᅜ࡟࠾ࡅࡿࠊ㐀⾑⣽⬊⛣

䠕䠅㼃㻴㻻䛾ືྥ䠖㻌

᳜⒪ἲࡢᬑཬ⋡ࠊ 㦵㧊࣭ᮎᲈ⾑ࣂࣥࢡࠊ⮖ᖏ⾑

ࣂࣥࢡࡢᅾࡾ᪉࡜බ㈝࡟ࡼࡿຓᡂࡢᐇែࠊἲᚊ᪋

⾜ᚋࡢᐇ᝟➼ࡀ࠶ࡿ⛬ᗘ᫂ࡽ࠿࡟࡞ࡗࡓ࡜⪃࠼

ࡿࠋࡑࡋ࡚ࡇࢀࡽࡣࠊ௒⯡᪂ࡓ࡟❧ἲ໬ࡉࢀࡓ͆㐀

⾑ᖿ⣽⬊⛣᳜᥎㐍ἲ㸦␎⛠㸧͇࡟ᇶ࡙ࡃㅖ᪋࡟཯

ᫎࡉࢀࡿ࡛࠶ࢁ࠺ࠋ

㸰䠅㻌 䛺䛚䚸⡿ᅜ䚸䝇䜲䝇➼䛻䛚䛔䛶䛿㐀⾑⣽⬊⛣᳜

㛵㐃ἲ᱌䛜୍㒊᪋⾜䛥䜜䛶䛔䜛䛜䚸≉䛻᪥ᮏ䛸㐀⾑

ᖿ⣽⬊⛣᳜䛾┦஫༠ຊ䛜㐍䜣䛷䛔䜛⡿ᅜ䛻䛴䛔䛶䚸

ྠᅜ㆑⪅䛾ᣍ⪸䛸⌧ᆅㄪᰝ䜢⾜䛳䛯䚹䛭䛾⤖ᯝ⡿

ᅜἲ䛜䛭䜜䜎䛷Ꮡᅾ䛧䛯CIBMTR䛸NMDP䜢䛭䛾 䜎䜎ㄆᐃ䛧ἲ䛾ಖㆤ䛸つไ䜢୚䛘䛯ᡤ䛜༳㇟ⓗ䛷䛒 䛳䛯䚹ᚑ䛳䛶CIBMTR䛿௒䜒䜴䜲䝇䝁䞁䝅䞁኱Ꮫ䛻 ᒓ䛧䚸䝕䞊䝍䝉䞁䝍䞊సᴗ⪅䛿ྠ኱Ꮫ䛾ᩍᐁ䛷䜒䛒 䜚⥆䛡䛶䛔䜛䜟䛡䛷䛒䜛䛜䚸䛭䛧䛶䛭䛾䛯䜑䛻

CIBMTR䛾䜰䜹䝕䝑䝭䜽䜰䜽䝔䜱䝡䝔䜱䞊䛜⥔ᣢ䛥䜜䚸

Ⓨᒎ䛧⥆䛡䛶䛔䜛䜟䛡䛷䛒䜛䛜䚸ᡃ䛜ᅜ䛾ሙྜ᪂䛯 䛺䝕䞊䝍䝉䞁䝍䞊䛿䛭䜜䜎䛷䛾኱Ꮫᖐᒓ䜢ᗫ䛧䚸⊂

❧䛧䛯⤌⧊䛷䛒䜛䛣䛸䛜ồ䜑䜙䜜䛶䛔䜛䛾䛷䚸䜰䜹䝕 䝭䝑䜽䜰䜽䝔䜱䝡䝔䜱䞊䜢⥔ᣢ䚸Ⓨᒎ䛥䛫䜛䛯䜑䛻᪂䛯 䛺௙⤌䜏䛾ᵓ⠏䛜ồ䜑䜙䜜䜛䛣䛸䛻䛺䜝䛖䚹㻌

䠏䠅㻌 ᣍ⪸䞉どᐹ஦ᴗ䛻䜘䜚䜒䛖୍䛴᫂䜙䛛䛻䛺䛳䛯䛾 䛿䚸㦵㧊䝞䞁䜽䚸⮖ᖏ⾑䝞䞁䜽䛾㛵ಀ䛸SPA㻛OPA䛾 ᐇែ䛷䛒䜛䚹⡿ᅜἲ䛿䚸䛭䛾ᙜึ䛛䜙᪤䛻ከ䛟Ꮡᅾ 䛧䛶䛔䛯Ẹ㛫⮖ᖏ⾑䝞䞁䜽䛾⤫ྜ䜢NMDP䛻᎑䛧䛶 䛔䜛䚹୍᪉ᡃ䛜ᅜ䛷䛿䛣䛾Ⅼ䛻䛴䛔䛶䛿᫂グ䛜↓䛔 䠄㦵㧊⛣᳜᥎㐍㈈ᅋ䛾௙஦䛸䛿᫂グ䛥䜜䛶䛔䛺䛔䠅䚹 ྈ䚸౑⏝⪅䛻䛸䛳䛶౑䛔຾ᡭ䛾Ⰻ䛔䝞䞁䜽ᶵᵓ䛻䛩 䜛䜘䛖䛻䚸䛸䛔䛖䛣䛸䛺䛾䛷䚸⡿ᅜ䛾ᐇែ䜢ཧ⪃䛻䛧䛴 䛴సᴗ䜢㐍䜑䜛䛣䛸䛜ᚲせ䛷䛒䜝䛖䚹㻌

㸲㸧WHOࡀ௚㡿ᇦࡢࣔࢹࣝ࡜⪃࠼࡚࠸ࡿ㐀⾑ᖿ

⣽⬊⛣᳜ୡ⏺ㄪᰝ㸦ࢧ࣮࣋࢖࡜ࣞࢪࢫࢺࣜ㸧ࡢ⢭

ᗘࢆୖࡆࡿ࡟ࡣࠊ᪂ἲ࡟ᇶ࡙ࡃᡃࡀᅜࡢ㐀⾑⣽⬊

⛣᳜ࢹ࣮ࢱࢭࣥࢱ࣮ࡢᶵ⬟ࢆྥୖࡉࡏࠊࢹ࣮ࢱ཰

㞟࣭ゎᯒᶵ⬟ࢆࡉࡽ࡟ྥୖࡉࡏࡿࡇ࡜ࡀࠊᅜෆࡢ

ࡳ࡛ࡣ࡞ࡃࠊ࢔ࢪ࢔ࣞ࣋ࣝࠊୡ⏺࡛ࣞ࣋ࣝࡶ㔜せ

࡛࠶ࡿࠋ

㻌 䠑䠅ᝈ⪅䞉䝗䝘䞊䛾Ᏻ඲ᛶ䜔⮫ᗋᡂ⦼䛻㛵䛩䜛䝕䞊㻌 䝍䛾䚸㻌 ୡ⏺つᶍ䛷䛾㞟ィ䛸ゎᯒ䛻㛵䛧䛶䛿䚸㻞㻜㻝㻟 ᖺᗘAPBMT㻘㻌WBMT䝃䞊䝧䜲䜢ᐇ᪋䛧䛯䚹䜰䝆䜰 ᆅ༊䛷㐀⾑ᖿ⣽⬊⛣᳜⣼ィᩘ䛜㻝㻜୓౛䚸ୡ⏺඲య 䛷㻝㻜㻜୓౛䜢䛭䜜䛮䜜✺◚䛧䛯䛣䛸䛜᫂䜙䛛䛻䛺䜛䛸 䛸䜒䛻䚸᭦䛻඲䛶䛾ᆅᇦ䛷ቑຍ䛾୍㏵䜢䛯䛹䛳䛶䛔 䜛䛣䛸䛜♧䛥䜜䛯䚹APBMT / WBMT䛜ಖ᭷䛧䛶䛔 䜛ᝈ⪅䝕䞊䝍䚸㻌 䜎䛯䝗䝘䞊䝕䞊䝍䛻䛴䛔䛶䚸㻌 ẚ㍑

᳨ウ䛷䛝䜛ᙧᘧ䜈䛾ኚ᥮䛻㛵䛧䛶䛿䚸⡿ᅜ䚸Ḣᕞ䚸 䜰䝆䜰䛷䛾ඹ㏻㡯┠䜢タᐃ䛧䠄Outcome Registry Form, Minimum Essential Data ase䠅㻘APBMT 䛸䛧䛶ึ䜑䛶䚸䜰䝆䜰ே䛻䛚䛡䜛⛣᳜ᚋ⏕Ꮡ᭤⥺䜢 ᥥ䛔䛯䚹ྛᅜ䛻䛚䛡䜛㐀⾑ᖿ⣽⬊⛣᳜䛾ᑐ㇟⑌ᝈ 䜔ேᩘ䛻㛵䛧䛶䛿䚸ඛ㏙䛾ୡ⏺䜰䞁䜿䞊䝖⤖ᯝ䛻䛚 䛔䛶グ㍕䛧䛯䚹㻌

䠒䠅ୡ⏺䛾㠀⾑⦕䝪䝷䞁䝔䜱䜰䝗䝘䞊䛾Ᏻ඲ᛶᢸಖ≧

ἣ䛿䚸ᡃ䛜ᅜ䛾㦵㧊⛣᳜᥎㐍㈈ᅋ䜒䛭䛾䝯䞁䝞䞊⤌

⧊䛾୍䛴䛷䛒䜛WBMT䛻䜘䛳䛶⿵㊊䛥䜜䛶䛚䜚䚸≉

䛻 ⥭ ᛴ ᭷ ᐖ ஦ ㇟ 䜢 ୡ ⏺ 䝺 䝧 䝹 䛷 Ⓨ ಙ 䛧 䛶 䛔 䜛 SEAR㻛SPEAR䝅䝇䝔䝮䛿᭷⏝䛷䛒䜛䚹ᡃ䛜ᅜ䛷䛣 䜜䜎䛷᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍䠄⾑⦕䝗䝘䞊䠅㻛㦵㧊

⛣᳜᥎㐍㈈ᅋ䠄㠀⾑⦕䝗䝘䞊䠅䛾䝗䝘䞊Ᏻ඲⿵㊊䝅 䝇䝔䝮䛿⾑⦕䝗䝘䞊䜢䜒ᑐ㇟䛸䛧䛶䛔䜛Ⅼ䚸୍᪥䛾㛗 䛜䛒䜛䛜䚸ᅜ㝿ᶆ‽䛷䛒䜛SEAR㻛SPEAR䛸䛾ᩚྜ

ᛶ䜢ྲྀ䜚䚸䛭䛣䜈䛾᝟ሗᥦ౪䜢䛧䛶䜖䛟ᚲせ䛜䛒䜝䛖䚹 ᑦ䚸⾑⦕䝗䝘䞊䜢䜒ᑐ㇟䛸䛩䜛ᡃ䛜ᅜⓎ䛾⪃䛘䛿䚸 WBMT㻌Consensus Document䠄ඛ㏙䠅䛾䜏䛺䜙䛪䚸 WBMT䛻䛒䜛㻡䛴䛾ᖖタጤဨ఍䛾୍䛴䛷䛒䜛䝗䝘䞊 ጤဨ఍䛾䝔䞊䝬䛻䜒ྲྀ䜚ධ䜜䜙䜜䛶䛔䜛䚹

㹃㸬⤖ㄽ

㐀⾑ᖿ⣽⬊⛣᳜ࡢไᗘ࡟㛵ࡍࡿᅜ㝿ẚ㍑ศᯒࡢ

14

ࡓࡵ࡟୺࡜ࡋ࡚ୡ⏺㐀⾑⣽⬊⛣᳜ࢿࢵࢺ࣮࣡ࢡ 㸦WBMT㸧ࢆ௓ࡋ࡚⾜ࡗࡓᅜ㝿᝟ሗ཰㞟࣭ゎᯒ ୪ࡧ࡟ᅜ㝿ពぢ஺᥮ࡣࠊᡃࡀᅜ࡛᪂ࡓ࡟ไᐃ࣭᪋

⾜ࡉࢀࡿ͇㐀⾑ᖿ⣽⬊⛣᳜᥎㐍ἲ㸦␎⛠㸧͇ࡢᐇ

㊶࡟᭷ព࡞᝟ሗࢆࡶࡓࡽࡋࡓࠋ

㹄㸬೺ᗣ༴㝤᝟ሗ

ᝈ⪅୪ࡧ࡟ࢻࢼ࣮࡟㛵ࢃࡿ೺ᗣ༴㝤᝟ሗࡣࠊᅜෆ

࡛ࡣ᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍ࠊ㦵㧊⛣᳜᥎㐍㈈ᅋ࡟

ࡼࡾࠊᾏእ࡛ࡣWMDA࡟ࡼࡾᤕᤊࡉࢀࠊ㟁Ꮚ፹ య➼࡟ࡼࡾ㏲ḟ඲ᅜࠊ඲ୡ⏺࡬Ⓨಙࡉࢀ࡚࠸ࡿࠋ

㹅㸬◊✲Ⓨ⾲

㸯ㄽᩥⓎ⾲

㸬㟷㞼ࠊ㣤⏣⨾ዉᏊࠊ㕥ᮌᚊᮁࠊᒣୗ༟ஓࠊ⚟

⏣㝯ᾈࠊ኱ᶫ୍㍤ࠊᑠᕝၨᜤࠊ㨣ሯ┿ோࠊ

㏆⸨ᛅ୍ࠊ㔠᳃ᖹ࿴ࠊ㯮ᕝᓠኵࠊᐑᮧ⪔୍㸧ࠊ

ఀ⸨ಇᮁࠊ⾨⸨ᚭஓࠊ∦ᒣ⩏㞝ࠊ๓⏣ဴ⏕ࠊ ᑠᑎⰋᑦ

⾑⦕㐀⾑ᖿ⣽⬊㸦㦵㧊࣭ᮎᲈ⾑㸧ࢻࢼ࣮ࡢኌ

᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍㞧ㄅ⮫ᗋ◊✲➨ᕳ

➨ྕ 㡫㡫 㸬

䠎䠊Minako Iida, Ritsuro Suzuki, Takashi Yoshida, Ken Ishiyama, Hiroyasu Kaya, Jun Taguchi, Atsushi Kikuta, Kaoru Kahata, Eiji Ohno, Koichi Miyamura, Yoshihisa Kodera

Outpatient peripheral blood stem cell collection in Japan: Donor follow-up survey by the Japan Society for Hematopoietic Cell Transplantation

July 31, 2012.᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍㞧ㄅ 1(2):

52-58.

㻟䠊Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kobayashi N, Fukuda T, Azuma H, Takanashi M, Mori T, Tsuchida M, Kawase T, Kawa K, Kodera Y, Kato S; for the Japan Marrow Donor Program and the Japan Cord Blood Bank Network.

Comparison of Unrelated Cord Blood

Transplantation and HLA-Mismatched Unrelated

Bone Marrow Transplantation for Adults with Leukemia.

Biol Blood Marrow Transplant. 2012 May;18(5):780-787. Epub 2011 Oct 18.

䠐䠊Minako Iida, Ritsuro Suzuki, Takashi Yoshida, Ken Ishiyama, Hiroyasu Kaya, Jun Taguchi, Atsushi Kikuta, Kaoru Kahata, Eiji Ohno, Koichi Miyamura, Yoshihisa Kodera

Outpatient peripheral blood stem cell collection in Japan: Donor follow-up survey by the Japan Society for Hematopoietic Cell Transplantation㻌(Outpatient PBSC collection in Japan)

᪥ᮏ㐀⾑⣽⬊⛣᳜Ꮫ఍㞧ㄅ.2012. 1(2): 52-58.㻌 䠑 䠊Nakata K, Takami A, Espinoza JL, Matsuo K,

Morishima Y, Onizuka M, Fukuda T, Kodera Y, Akiyama H, Miyamura K, Mori T, Nakao S; Japan Marrow Donor Program.

The recipient CXCL10 +1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation.

Clin Immunol. 2013 Feb;146(2):104-11.

㻢䠊Espinoza JL, Takami A, Onizuka M, Morishima Y, Fukuda T, Kodera Y, Akiyama H, Miyamura K, Mori T, Nakao S; Japan Marrow Donor Program.

Recipient PTPN22 -1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies.

Biol Blood Marrow Transplant. 2013 Feb;19(2):240-6.

䠓䠊Gratwohl A, Baldomero H, Gratwohl M, Aljurf MD, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D.

Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.

Haematologica. 2013 Mar 18. [Epub ahead of print]

㸶㸬Halter JP, Walraven SM, Worel N, Bengtsson

M, Hagglund H, Faveri G N, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwi eser D, Gratwohl A, Kodera Y and Confer D. A llogeneic hematopoietic stem cell donation: standa rdized assessment of donor outcome data-A WB MT consensus document. Bone Marrow Transplant. 2012, 1-6.

㸰Ꮫ఍Ⓨ⾲

㻝㻕㻌Y. Kodera, S. Chiba, S. Kato, S. Taniguchi forJS HCT, JMDP and JCBBN Impact of earth quake/nu clear accident on stem cell transplants in Japan.

38^th Annual Meeting of the European Group for Bl ood and Marrow Transplantation

Geneva, Switzerland, 1-4 April 1,2012 Yoshihisa Kodera

Plenary Session 2 : Donor Registry and Clinical HPC outcomes

Results from the Asian-Pacific registries

9^th International Donor Registry Conference (IDRC)

2012 Sydney, Australia, 1-5 May 2012

㻟㻕㻌ᑠᑎⰋᑦ

Advances of hematopoietic stem call transplantation in Asia-Pacific region

ʊThe current status and the future aspects of hematopoietic stem cell transplantation in japan, in APBMT and in WBMT Ɇ

2012 ύỤ┬㐀⾑ᖿ⣽⬊⛣᳜◊✲఍

Hangzhou, China, May 15, 2012 Yoshihisa Kodera

Battles to post-transplant relapse-Japanese experiences

Shanghai Forum for Hematopoietic Stem Cell Transplantation 2012

Shanghai, China, 26-28 July 2012

Yoshihisa Kodera, Minako Iida, Yoshiko Atsuta, Yoshimi Ayami, Rie Hyo, Ritsuro Suzuki, for

APBMT /WBMT The creation and the advances of APBMT The 39^th Annual General Meeting/Scientific Conference of Nigerian Society for

Haematological and Blood Transfusion Lagos, Nigerian, 18-20 September 2012

Yoshihisa Kodera

Management of complications of Haematopoietic Stem Cell Transplantation

The 39^th Annual General Meeting/Scientific Conference of Nigerian Society for Haematological and Blood Transfusion Lagos, Nigerian, 18-20 September 2012 Kayoko Yamada, Espinoza J. Luis, Makoto Onizuka,

Takahiro Fukuda, Takakazu Kawase, Eriko Morishita, Yoshihisa Kodera, Yasuo Morishita, Shigeki Otake, Shinji Nakao, Akiyoshi Takami

Perforin polymorphism predicts transplanted outcomes after HLA-matched unrelated BMT The 74^th Annual Meeting of the Japanese Society of

Hematology Kyoto, 19-21 October 2012

Masato Shikami, Tomohiro Horio, Akihito

Hiramatsu, Masaya Watarai, Mayuko Gotou, Mineaki Goto, Miyuki Takahashi, Shohei Mizuno, Hiroko Komatubara, Motonori Mizutani, Kazuto Suganuma, Norikazu Tsunekawa, Hidesuke Yamamoto, Motohiro Wakabayashi, Ichiro Hanamura, Akira Imamura, Hidetsugu Mihara, Hidefumi Kato, Yoshihisa kodera, Hirosh Miwa, Megumi Enomoto, Hironobu

Shimizu, Masakazu Nitta

Clinical manifestation of AML with erythroid hyperplasia

The 74^th Annual Meeting of the Japanese Society of

Hematology Kyoto, 19-21 October 2012

㻌

㹆㸬▱ⓗ㈈⏘ᶒࡢฟ㢪࣭Ⓩ㘓≧ἣ㸦ணᐃࢆྵࡴࠋ㸧

≉チྲྀᚓ ≉࡟↓ࡋ

16

ᐇ⏝᪂᱌Ⓩ㘓 ≉࡟↓ࡋ ࡑࡢ௚

㻌

ู⣬㸲

◊✲ᡂᯝࡢห⾜࡟㛵ࡍࡿ୍ぴ⾲

㞧ㄅ Ⓨ⾲⪅Ặྡㄽᩥࢱ࢖ࢺࣝྡⓎ⾲ㄅྡᕳྕ࣮࣌ࢪฟ∧ᖺ Gratwohl A, Baldomero H, Gratwohl M, Aljurf MD, Bouzas LF, HorowitzM, KoderaY, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D.

㻌

Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.

㻌

Haematologica.Epub ahead of㻌print

㻌

2013 Halter JP, Walraven SM, Worel N, Bengtsson M, Hagglund H, Faveri G N, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y and Confer D

Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data-A WBMTconsensus document.

Bone Marrow Transplant.1-6.2012

22

24

26

28

30

32

34

36

38

40

42

44

46

48

50

52

54

56

58

60

62

64

66